[COMPANY_011] Pasteur ADC01 
Protocol Version 3.0  
Confidential/Proprietary Information  
Page 1 of 71 Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria 
Toxoid, and Acellular Pertussis Vaccine Adsorbed (SP0173) in 
Healthy Adolescents, Adults, and Older Adults  
A Phase I/II, randomized, modified double-blinded, multi -center, active comparator, dose and 
formulation ranging, step-down study to assess the safety and immunogenicity of SP0173 in 
healthy adolescents, adults, and older adults conducted in the US.  
Clinical Trial Protocol, Amendment 2 
Health Authority File Numbers : BB-IND#: [ZIP_CODE] 
WHO Universal Trial Number 
(UTN): U1111-1161-3027 
Trial Code: ADC01 
Development Phase:  Phase I/II 
Sponsor:  [COMPANY_011] Pasteur Inc.  
[ADDRESS_1266719] : SP0173 (Tetanus toxoid [T] , diphtheria toxoid [d] , pertussis toxoid [PT], 
filamentous hemagglutinin [FHA], pertactin [ PRN], fimbriae types 2 and 3 
[FIM]).   
Form/Route: Liquid/Intramuscular (IM)  
Indication For This Study:  Single dose for i ndividuals ≥ 10 years of age 
Manufacturer:  Same as Sponsor  
Coordinating Investigators:  
Sponsor’s Responsible Medical 
Officer: , Sano fi Pasteur  Inc. 
Product Safety Officer:  
, [COMPANY_011] Pasteur  Inc. 
Clinical Trial Manager:  
, [COMPANY_011] Pasteur Inc.  
Version and Date of the Protocol:  Version 3.0 dated 13 May 2016 
This protocol  version 3.0 is the second amendment to the initial trial protocol V ersion 1.0 dated 22 July 2015.  It is 
preceded by [CONTACT_11827] 1.0 (protocol Version 2.0 dated 29 September 2015).  
Information contained in this publication is the property of [COMPANY_011] Pasteur and is confidential. This information may not be 
disclosed to third parties without written authorization from [COMPANY_011] Pasteur. This document may not be reproduced, stored in a 
retrieval system, or transmitted in any form or by [CONTACT_61076] –electronic, mechanical recording, or otherwise –without prior 
authorization from [COMPANY_011] Pasteur. This document must be retur ned to [COMPANY_011] Pasteur upon request.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 1 of 72
Study ID: [REMOVED]
[COMPANY_011] Pasteur ADC01 
Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266720] ..................................................................... 22  
1.3 Potential Benefits and Risks ........................................................................................... 23  
1.3.1  Potential Benefits to Subjects  ....................................................................................... 23  
1.3.2  Potential Risks to Subjects ........................................................................................... 23  
1.4 Rationale for the Trial  ..................................................................................................... 23  
2 Trial Objectives  ............................................................................................................... 24  
2.1 Observational Objectives  ................................................................................................ 24  
3 Investigators and Trial Organization ............................................................................ 24  
4 Independent Ethics Committee/Institutional Review Board  ...................................... 25  
5 Investigational Plan  ......................................................................................................... 25  
5.1 Description of the Overall Trial Design and Plan ........................................................... 25  
5.1.1  Trial Design  .................................................................................................................. 25  
5.1.2  Justification of the Trial Design  ................................................................................... 26  
5.1.3  Trial Plan  ...................................................................................................................... 27  
5.1.4  Visit Proc edures ............................................................................................................ 27  
5.1.5  Planned Trial Calendar ................................................................................................. 30  
5.1.6  Early Safety Data Review ............................................................................................. 31 
5.2 Enrollment and Retention of Trial Population ................................................................ 32  
5.2.1  Recruitment Procedures  ................................................................................................ 32  
5.2.2  Informed Consent Procedures ...................................................................................... 32  
5.2.3  Screening Criteria  ......................................................................................................... 33  
5.2.4  Inclusion Criteria  .......................................................................................................... 33  
5.2.5  Exclusion Criteria  ......................................................................................................... 33  
5.2.6  Medical History  ............................................................................................................ 35  
5.2.7  Contraindications for Subsequent Vaccinations ........................................................... 35  
5.2.8  Conditions for Withdrawal ........................................................................................... 35  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 2 of 72

[COMPANY_011] Pasteur ADC01 
Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266721] .............................................................................................. 38  
[IP_ADDRESS]  Composition  ............................................................................................................... 38  
[IP_ADDRESS]  Preparation and Administration  ................................................................................. 39  
[IP_ADDRESS]  Dose Selection and Timing ........................................................................................ [ADDRESS_1266722] 1 ........................................................................................ 39  
[IP_ADDRESS]  Composition  ............................................................................................................... 39  
[IP_ADDRESS]  Preparation and Administration  ................................................................................. 40  
[IP_ADDRESS]  Dose Selection and Timing ........................................................................................ [ADDRESS_1266723] 2 ........................................................................................ 40  
[IP_ADDRESS]  Composition  ............................................................................................................... 40  
[IP_ADDRESS]  Preparation and Administration  ................................................................................. 41  
[IP_ADDRESS]  Dose Selection and Timing ........................................................................................ [ADDRESS_1266724] Shipment, Storage, and Accountability ........................................................... 41  
[IP_ADDRESS]  Product Shipment ....................................................................................................... 41  
[IP_ADDRESS]  Product Storage .......................................................................................................... 42  
[IP_ADDRESS]  Product Accountability ............................................................................................... 42  
6.3.3  Replacement Doses ....................................................................................................... 42 
6.3.4  Disposal of Unused Products ........................................................................................ 42  
6.3.5  Recall of Products ......................................................................................................... 42  
6.4 Blinding and Code-breaking Procedures ........................................................................ 42  
6.5 Randomization and Allocation Procedures ..................................................................... 44  
6.6 Treatment Compliance  .................................................................................................... 44  
6.7 Concomitant Medications and Other Therapi[INVESTIGATOR_014]  ............................................................. 44  
7 Management of Samples ................................................................................................. 45  
7.1 Sample Collection  ........................................................................................................... 45  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 3 of 72

[COMPANY_011] Pasteur ADC01 
Protocol Version 3.0  
Confidential/Proprietary Information  
Page 4 of 71 7.1.1  Serum Samples  ............................................................................................................. 45  
7.1.2  Blood Samples for Cellular Immunity Assessment  ...................................................... 45  
7.2 Sample Preparation  ......................................................................................................... 46  
7.2.1  Serum Samples  ............................................................................................................. 46  
7.2.2  Blood for Cellular Immunity Assessment  .................................................................... 46  
7.3 Sample Storage and Shipment ........................................................................................ 46  
7.4 Future Use of Stored Serum/Blood Samples for Research  ............................................. 47  
8 Clinical Supplies  .............................................................................................................. 47  
9 Endpoints and Assessment Methods  ............................................................................. 47  
9.1 Primary Endpoints and Assessment Methods ................................................................. 47  
9.1.1  Safety ............................................................................................................................ 47  
9.1.2  Immunogenicity ............................................................................................................ 48  
9.1.3  Efficacy ......................................................................................................................... 48  
9.2 Secondary Endpoints and Assessment Methods ............................................................. 48  
9.2.1  Safety ............................................................................................................................ 48  
9.2.2  Immunogenicity ............................................................................................................ 48  
9.2.3  Efficacy ......................................................................................................................... 48  
9.3 Observational Endpoints and Assessment Methods ....................................................... 48  
9.3.1  Safety ............................................................................................................................ 48  
[IP_ADDRESS]  Safety Definitions  ....................................................................................................... 48  
[IP_ADDRESS]  Safety Endpoints ........................................................................................................ 51  
[IP_ADDRESS]  Safety Assessment Methods ....................................................................................... 51  
[IP_ADDRESS].[ADDRESS_1266725] -Vaccination Surveillance Period  ................................................... 51  
[IP_ADDRESS].2  Reactogenicity (Solicited Reactions From  Day 0 to Day 7 After Vaccination) ...... 52  
[IP_ADDRESS].3  Unsolicited Non-serious Adverse Events From D0 to V02 After Vaccination ....... 55  
[IP_ADDRESS].4  Serious Adverse Events  ........................................................................................... 56  
[IP_ADDRESS].[ADDRESS_1266726]  .......................................................................... 56  
[IP_ADDRESS].6  Medically Attended Adverse Events  ....................................................................... 56  
[IP_ADDRESS].7  Assessment of Causality  .......................................................................................... 57  
9.3.2  Immunogenicity ............................................................................................................ 57  
[IP_ADDRESS]  Immunogenicity Endpoints ........................................................................................ 57  
[IP_ADDRESS]  Immunogenicity Assessment Methods ...................................................................... [ADDRESS_1266727] Has Completed the Study ...................... 60  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 4 of 72

[COMPANY_011] Pasteur ADC01 
Protocol Version 3.0  
Confidential/Proprietary Information  
Page 5 of 71 10.4  Assessmen t of Causality  ................................................................................................. 60  
10.5  Reporting SAEs to Health Authorities and IECs / IRBs ................................................. 60  
11 Data Collection and Management ................................................................................. 60  
11.1  Data Collection and CRF Completion ............................................................................ 60  
11.2  Data Management  ........................................................................................................... 61  
11.3  Data Review .................................................................................................................... 62  
12 Statistical Methods and Determination of Sample Size  ............................................... 62  
12.1  Statistical Methods  .......................................................................................................... 62  
12.1.1  Statistical Methods for Demographics and Background Characteristics ..................... 62  
12.1.2  Statistical Methods for Observational Objectives  ........................................................ 63  
12.2  Analysis Sets ................................................................................................................... 64  
12.2.1  Full Analysis Set ........................................................................................................... 64  
12.2.2  Safety Analysis Set  ....................................................................................................... 64  
12.2.3  Per-Protocol Analysis Set ............................................................................................. 64  
12.2.4  Populations Used in Analyses ...................................................................................... 65  
12.3  Handling of Missing Data and Outliers .......................................................................... 65  
12.3.1  Safety ............................................................................................................................ 65  
12.3.2  Immunogenicity ............................................................................................................ 65  
12.4  Interim/Preliminary Analysis  .......................................................................................... 65  
12.5  Determination of Sample Size and Power Calculation  ................................................... 66  
13 Ethical and Legal Issues and Investigator/Sponsor Responsibilities .......................... [ADDRESS_1266728] of the Trial/Good Clinical Practice  ...................................................... [ADDRESS_1266729]  ................................................................................................................. 70  
15 Signature [CONTACT_68615]  ............................................................................................................... 71  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 5 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266730] of Tables  
Table 5.1: Study groups and vaccine formulations .........................................................................26  
Table 9.1: Solicited injection site reac tions : terminology, definitions, and intensity scales ..........53  
Table 9.2: Solicited systemic reactions: terminology, definitions, and intensity scales .................54  
 
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 6 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 7 of 71 Synopsis 
Company:  [COMPANY_011] Pasteur  
Investigational Product:  SP0173 (Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular 
Pertussis Vaccine Adsorbed [Tda p Vaccine])  
Active Substances:  Tetanus toxoid (T) , diphtheria toxoid (d), pertussis toxoid (PT) , 
filamentous  hemagglutinin (FHA) , pertactin (PRN), fimbriae types 2  and 
3 (FIM). 
  
Title of the Trial:  Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (SP0173) in Healthy Adolescents, Adults, and Older  Adults 
Development Phase:  Phase I/II 
Coordinating Investigator:   
 
[INVESTIGATOR_504895]:  This will be a multi -center study conducted at approximately 20 centers in 
the US. 
Investigators and sites  are listed in the “List of Investigators, Trial 
Centers, and Sponsor’s Personnel Involved in the Trial Document.”  
Planned Trial Period: 4Q 2015 to 1 Q 2017 
Trial Design and Methodology:  This will be a Phase I/II, randomized, modified double -blinded, mult i-
center, active comparator, dose and formulation  ranging, step -down study 
to assess the safety and immunogenicity of SP0173 in healthy adolescents, 
adults, and older adults . 
Age groups are defined as follows:  
• Adolescents: age 10–18 years  
• Adults: age 19 –64 years 
• Older Adults: age  ≥ 65 years  
Subjects will be stratified by [CONTACT_903093] 6 vaccination groups:  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 7 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 8 of 71  Table S1: Study group and vaccine formulations  
 
 
 
   
 
  
 
  
  
  
 
 
 
      
  
        
 
        
 
        
  
        
  
        
         
 
  
 
All subjects will receive a single dose of vaccine, and will provide a blood 
sample for immunogenicity assessment at baseline pre -vaccination  Visit 
(V)[ADDRESS_1266731] -vaccination V02 (30days + 14 days) . A subset of subjects 
(36 adolescents, 60 adults , and 60 older adults) enrolled in all groups will 
provide an additional blood sample  at baseline pre-vaccination  V01 and at 
post-vaccination V02  (30days +7 days) for exploratory testing of 
parameters of cell -mediated immunity  (CMI). The results of that testing 
will be described in a separate report.  
Subjects will be monitored for immediate unsolicited systemic adverse events (AEs) for 30 minutes after  vaccination. Solicited reactions 
(injection site and systemic) will be collected from Day (D)[ADDRESS_1266732]-
vaccination.  
Unsolicited AE informat ion will be collected from V01 (D0) to 
V02 (D30-D44) and serious adverse event (SAE) information will be 
collected throughout the study period from V01 to the end of the 6- month 
follow-up, i.e. D0 through D180 after vaccination.  
Medically -attended adverse event ( MAAE) information will be collected 
throughout the study from V0 1 through V02 (as part of the collection of 
unsolicited AE information) and from V0 2 through the end of the 6 -month 
follow-up (as MAAE information ).
 
Early Safety Data Review:  The safety of the investigational product will be continuously monitored by [CONTACT_1034]. Early safety data review (ESDR) will be performed, the 
goal of which is to allow for a cautious, step wise approach to vaccine 
administration. An initial internal safety review  (during which enrollment 
in the study between age cohorts will be paused)  is planned when all 
subjects in the adu lt age cohort (n= 450) have been vaccinated and have 
provided safety data for V01 through V02 post-vaccination, using the data 
collection methods described in the protocol.  The interim safety review is 
to occur prior to the start of enrollment of adolescent s and elderly  The 
safety data collected will be entered into the electronic case report forms (eCRFs), and will be summarized and reviewed in a per-group partially 
blinded (group unblinded) fashion by [CONTACT_1034]. It is understood that this 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 8 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266733] to 
validation and database lock.  
 The following safety parameters will be assessed as part of the early 
safety review  and the continuous safety analyses : 
• Immediate unsolicited AEs  
• Solicited injection s ite and systemic reactions  
• Unsolicited AEs  
• SAEs 
• MAAEs 
 Enrollment will be paused during the ESDR, and the data will be 
examined for the following alert thresholds defined for this study:  
• Extensive limb swelling (ELS) among ≥ 3% recipi[INVESTIGATOR_903085] s 
• Any life-threatening event  or death considered related to vaccination 
by [CONTACT_903094][INVESTIGATOR_903086] -group partially-blinded 
safety review, a decision will be made as to whether enrollment of the affected group in the study will be allowed to continue. Only in case of 
further concern, complete unblinding and further in- depth review of 
safety data will be conducted . Continuation will be determined pending 
final results of the early safety review. If the risk for certain 
formulation(s) has been determined as high, enrollment  of the next age 
groups (adolescents and older adults)  for the respective formulation will 
not proceed. 
The usual and ongoing process of monitoring safety signals outside of 
those specified in the protocol- defined early interim safety analysis will 
continue unchanged.  
Apart from the ESDR and the ongoing safety review , the study may be 
interrupted at any time if new data about the investigational product 
become available, and/or on advice of the Sponsor, the Institutional Ethics 
Committees (IEC)/Institutional Review Boards (IRB), or the governing 
regulatory authorities in the US  where the study is taking place.  
If the study is prematurely terminated or suspended, the Sponsor will 
promptly inform the Investigators, the IECs/IRBs, and the regulatory authorities of the reason for termination or suspension. If the study is 
prematurely terminated for any reason, the Investigator will promptly inform the study subjects / subjects’ parents/guardians and should assure 
appropriate therapy and follow- up.
 
Observational Objectives:  Safety / Reactogenicity  
• To describe the safety profile of each SP0173 investigational 
formulation. 
Immunogenicity 
• To describe the immunogenicity of each SP0173 investigational 
formulation.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 9 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 10 of 71 Observational Endpoints:  Safety / Reactogenicity  
• Occurrence, nature (Medical Dictionary for Regulatory Activities 
[MedDRA] preferred term), duration, intensity, action taken, and relationship to vaccination of any unsolicited systemic AEs reported 
in the 30 minutes after vaccination.  
 • Occurrence, time to onset, number of days of occurrence, action 
taken, and intensity of solici ted (prelisted in the subject diary card 
[DC] and eCRF) injection site reactions and systemic reactions 
occurring through D7 after vaccination.  
• Occurrence, nature (MedDRA preferred term), time to onset, 
duration, intensity, action taken, and relationship t o vaccination (for 
systemic AEs only) of unsolicited (spontaneously reported) AEs occurring from vacci nation through 30 days after vaccination . 
• Occurrence, nature (MedDRA preferred term), time to onset, 
duration, intensity, seriousness criteria, relationsh ip to vaccination, 
and outcome of SAE s from V01 to the 6- month follow -up for all 
groups after vaccination. 
• Occurrence, nature (MedDRA preferred term), time to onset, 
duration, intensity, seriousness criteria, relationship to vaccin ation, 
and outcome of MAAEs from V02 to the 6- month follow -up for all 
groups after vaccination.  
Immunogenicity 
• Anti-pertussis (PT, FHA, PRN, and FIM) antibody concentrations 
pre- and post-vaccination measured by [CONTACT_28745]- linked 
immunosorbent  assay (ELISA) . 
• Anti-diphtheria antitoxin concentration pre - and post-vaccination 
assessed by [CONTACT_903095] . 
• Anti-tetanus antitoxin concentration pre - and post-vaccination 
measured by [CONTACT_6428] . 
Planned Sample Size:  A total of 1350 subjects are planned to be enrolled and randomized to 1 of 
6 study groups. Within each group subjects will be stratified by [CONTACT_878334] a 
1:1:1 ratio as shown below.  
Table S2: Randomization by [CONTACT_2060].  
 
Study 
group  
Vaccine 
formulation  
Pertussis  
Adjuvant  Subjects, N  
10–18 
years 19-64 
years ≥ 65 
years 
1 SP0173-low  75 75  75 
2 SP0173-middle  75 75 75 
3 SP0173-middle  75  75 75 
4 SP0173-high  75 75 75 
5 Adacel® control  75  75 75 
6 BOOSTRIX® 
control  75 75 75 
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 10 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 11 of 71 Schedule of Study Procedures : Vaccination  
All subjects will be randomized to receive 1 dose of an SP0173 
formulation, Adacel®, or BOOSTRIX®. 
 Blood sampling  
All subjects will be asked to provide a pre -vaccination blood sample at 
V01 (D0) and a post-vaccination sample at V02 (30 days +14 days) . 
A subset of subjects enrolled in all groups will provide an additional 
blood sample  at baseline ( pre-vaccination at V0 1) and a post-vaccination 
sample at V02 ( 30days +7 days) for exploratory testing of CMI 
parameters.  
Collection of safety data  
• All subjects will be observed for 30  minutes after vaccination  and 
any unsolicited systemic AEs occurring during tha t time will be 
recorded as i mmediate unsolicited systemic AE s in the eCRF. 
• The subjects or subject’s  parent/guardian will record information 
about solicited reac tions (injection site  and systemic)  in a DC from 
D0 to D7 post-vaccination. Unsolicited AEs  and SAEs  will be 
recorded i n the DC between V01 and V0 2. 
• If the subject devel ops a Grade 3  solicited injection site (including 
ELS) or systemic AE  the subject or subject’s parent/guardian is 
required to contact [CONTACT_29261] . The site staff must attempt 
for the subject to be seen at t he study site within 24 hours to assess 
the extent of the reaction.  
• Staff will contact [CONTACT_35323]’ s parent/guardian by 
[CONTACT_72856] D8 (+3 days) to identify the occurrence of any SAE , 
Grade 3 solicited adverse reactions (including  ELS) not yet reported 
and to remind him/her to complete t he DC up to V02 and to bring it 
back at V0 2. 
• At V02, the completed DC will be revie wed with the subject or 
subject’s parent/ guardian and the DC will be collected . The subject or 
subject’s parent /guardian will recei ve a memory aid (MA) to record 
information about unsolicited A Es from V 02 until the 6 -month 
(+14 days) telephone call.  
• Staff will contact [CONTACT_903096]’s p arent/guardian by 
[CONTACT_1381] 6 months (+14 days) post -vaccination to review the MA 
and identify the occurrence of any MAAEs* or SAEs that may not 
have been reported. 
• MAAEs that occur from V01 (D0) to V02 will be rec orded as 
unsolicited AEs on the DC as part of the unsolicited AEs collected 
for this post-vaccination period. MAAE that occur from V0 2 to the 
long-term safety phone call at approximately 6 months after 
vaccination will be r ecorded as unsolicited AEs  in the MA. An 
MAAE that occurs within t he study period and meets the definition 
of an SAE should be reported only as an SAE. 
*Note: An MAAE is defined, for the purpose of this study, as a new onset 
of a condition that prompts the subject or subject’s parent/guar dian to 
seek unplanned medical advi ce at a physician’s office or Emergency 
Department. This definition excludes pre -planned medical office visits for 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 11 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266734] made over the 
phone or by [CONTACT_903097] a physician office visit for the 
purpose of MAAE  collection . 
• The subject or subject’s parent/ guardian will be asked to notify th e 
site immediately about potential SAEs at any time during the trial . 
Duration of Participation in the Trial: The duration of each subject’s participation in the study will be 
approximately 6 months (180 days + 14 days) . 
Investigational Product:  SP0173: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acell ular 
Pertussis Vaccine Adsorbed ( [COMPANY_011] Pasteur Limited, Toronto, ON, 
Canada) 
 Form: Liquid  
 Each 0.5 m L dose is formulated to contain ( exact amounts of some 
ingredients will vary based on the dose specified for the partic ular 
randomized group [Table S3]). 
 
    
     
     
   
   
    
 
 
 Table S3: SP0173 investigational f ormulations  
 
 
 
  
 
 
  
 
  
  
  
 
 
       
  
        
 
        
 
        
  
        
 
 Route: Intramuscular (IM)  
 Batch Number:  CD0097AA, CD0100AA, CD0102AA, CD0103AA  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 12 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266735]: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular 
Pertussis Vaccine Adsorbed ( [COMPANY_011] Pasteur Limited, Toronto, ON, 
Canada) 
 Form: Liquid  
 Composition : Each 0.5 mL dose is formulated to contain :  
Active Ingredients:  
Tetanus Toxoid ( T)    5 Lf 
Diphtheria Toxoid (d)     2 Lf 
Acellular Pertussis  
 Pertussis Toxoid (PT)     2.5 μg 
 Filamentous H emagglutinin (FHA)  5 μg  
 Pertactin (PRN)        3 μg  
 Fimbriae Types 2 and 3 (FIM)   5 μg 
 Other Ingredients:  
1.5 mg    AlPO4 adjuvant (0.33 mg aluminum) ,  
0.6% v/v 2 -phenoxyethanol  
 Route: IM 
 Batch Number:  C4774AA  
Control Prod uct: BOOSTRIX®: Tetanus Toxoid, Reduced Diphtheria Toxoid and 
Acellular Pertussis Vaccine, Adsorbed (GlaxoSmithKline Biologicals, 
Rixensart, Belgium , and [COMPANY_001] Vaccines and Diagnostics GmbH 
Marburg, [LOCATION_013] ) 
 Form: Liquid  
 Composition: Each 0.5 mL dose contains:  
Active Ingredients:  
Tetanus Toxoid (T)     5 Lf 
Diphtheria Toxoid (d)     2.5 Lf 
Acellular Pertussis  
 Pertussis Toxoid (PT)    8 μg 
  Filamentous Hemagglutinin (FHA)  8 μg 
 Pertactin (PRN)      2.5 μg 
 Other Ingredients:  
4.5 mg sodium chloride, < 0.39 mg aluminum (AlOOH adjuvant),  
< 100 µg residual formaldehyde, < 100 µg polysorbate 80 (Tween 80)   
 Route: IM 
 Batch Number:  Commercial product to be supplied by [CONTACT_30107].  
Inclusion Criteria:  An individual must fulfill all of the following criteria in order to be 
eligible for study enrollment:  
1) Aged 10 to 18 years, 19 to 64 years, or ≥ 65 years on the day of 
inclusion.  
2) Informed consent form has been signed and dated by [CONTACT_423] , or 
assent form has been signed and dated by [CONTACT_903098]/guardian  
3) Subject or subject and parent/guardian able to attend all scheduled 
visits and to comply with all study procedures  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 13 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 14 of 71 Exclusion Criteria:  An individual fulfilling any of the following criteria is to be excluded 
from study enrollment:  
 1) Subject is pregnant, or lactating, or of childbearing potential (to be 
considered of non -childbearing potential, a female must be pre-
menarche or post -menopausal for at least [ADDRESS_1266736] 4 weeks after 
vaccination. ) 
 2) Participation at the time of study enrollment (or in the 4 weeks 
preceding the study vaccination) or planned participation during the 
present study period in another clinical trial investigating a vaccine, 
drug, medical device, or medical procedure .  
 3) Received any vaccine in the 4 weeks preceding the trial vaccination 
or planned recei pt of any vaccine between V01 and V0 2. For 
influenza vaccine only, defer if received in the 14 -day period prior to 
enrollment or scheduled to receive in the 14- day period a fter 
enrollment.  
 4) Known or suspected receipt of a tetanus  toxoid, reduced diphtheria 
toxoid, and acellular pertussis  (Tdap) vaccine or Tdap-containing  
vaccine at any point in time, or receipt of a tetanus and diphtheria 
containing vaccine in the preceding  5 years. 
 5) Receipt of immune globulins, blood or blood -derived products in the 
past 3 months.  
 6) Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti -cancer chemotherapy or 
radiation therapy within the preceding 6 months, or long -term 
systemic corticosteroids therapy (prednisone or equivalent for more 
than [ADDRESS_1266737] 3 months).  
 7) History of diphtheria, tetanus, or pertussis infection (confirmed 
either serologically or microbiologically).  
 8) Known or suspected systemic hypersensitivity to any of the vaccine 
components or history of life -threatening reaction to the study 
vaccine or a vaccine containing the same substances.  
9) Laboratory- confirmed/self -reported thrombocytopenia or bleeding 
disorder contraindicating IM vaccination.  
10) Bleeding disorder, or receipt of anticoagulants in the 3 weeks 
preceding inclusion, contraindicating IM  vaccination  
11) History of encephalopathy (e.g., coma, decreased level of consciousness, or prolonged seizures) not att ributable to another 
identifiable cause within 7 days of administration of a previous dose 
of diphtheria and tetanus toxoids and pertussis (DTP), or diphtheria 
and tetanus toxoids and acellular pertussis (DTaP) vaccine  
12) Deprived of freedom by [CONTACT_903099], or in an 
emergency setting, or hospi[INVESTIGATOR_29476].  
13) Current alcohol abuse or drug addiction.  
14) Chronic illness  that, in the opi[INVESTIGATOR_871], is at a stage 
where it might interfere with trial conduct or completion.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 14 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 15 of 71  15) Moderate or severe acute illness/infection (according to Investigator 
judgment) on the day of vaccination or febrile illness (temperature 
≥ 100.4°F). A prospective subject should not be included in the 
study until the condition has resolved or the febrile ev ent has 
subsided. 
 16) Identified as an Investigator or employee of the Investigator or study 
center with direct involvement in the proposed study, or identified as 
an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the 
proposed study.  
Statistical  Methods:  Demographics  
Summaries of the recruitment and baseline demographic characteristics of the study subjects will be presented. The number of subjects enrolled and their age at  enrollment (mean, median, and minimum and maximum), sex, 
and ethnic origin will be summarized, along with the number and 
description of protocol violations. 
Safety / Reactogenicity
 
The number and percentage of subjects reporting any solicited injection 
site reactions and solicited systemic reactions will be summarized by 
[CONTACT_2060], intensity (Grade  1, Grade 2, and Grade 3), and period (D0 to 
D3, D4 to D7, and D 0 to D7 after vaccination) for each reaction term. For 
a time period in which more than [ADDRESS_1266738] (Clopper -Pearson) 2 -sided 95% confidence 
intervals (CIs) will be calculated for the percentages.  
 Immediate reactions, u nsolicited AEs  (including MAAEs), and SAEs  will 
be coded and presented by [CONTACT_903100] (SOC). The number and percentage of subjects reporting safety 
findings will be summarized by [CONTACT_903101],  and 
SOC that has at least [ADDRESS_1266739] -vaccination GMCs to  the 
following :  
 • In adolescents and adults: booster response rates and antibody GMCs 
after a single Adacel® dose  
 • In older adults: booster response rates to pre -determined criteria and 
antibody GMCs after 3 doses of DTaP (Daptacel®) vaccine given to 
infants in the historical Sweden I efficacy trial (for FHA, PRN and 
FIM) or aft er 4 doses of Daptacel vaccine given to per -protocol 
subjects in [COMPANY_011] Pasteur Study M5A10 (for PT)  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 15 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266740]-vaccination GMCs 
after a single Adacel® dose.  
Booster resp onse rates partially adjust for individual and population 
differences in pre -vaccination antibody concentrations.  
The criteri a for demonstrating a pertussis booster response are as follows:  
• If the pre-booster vaccination concentration is < 4xLLOQ, then the 
post-booster vaccination concentration is ≥ 4x the pre -booster 
concentration*  
• If the pre-booster vaccination concentration is ≥  4xLLOQ, then the 
post-primary vaccination concentration is ≥ 2 x the pre-booster 
concentration  
* Pre-booster vaccination concen trations <  LLOQ will be converted to 
LLOQ for purposes of calculating this booster response.  
 
For diphtheria and tetanus the criteria for demonstrating a booster 
response are as follows:  
• Subjects whose pre -vaccination antibody concentrations  are 
< 0.1 IU/mL will demonstrate the booster response if they have a 
post-vaccination level ≥ 0.4 IU/mL  
 • Subjects whose pre -vaccination an tibody concentrations are ≥ 
0.1 IU/mL but < 2.0 IU/mL will demonstrate the booster response if 
they have a 4- fold rise (i.e., post -/pre-vaccination ≥ 4) 
• Subjects whose pre -vaccination antibody concentrations are 
≥ 2.0 IU/mL, will demonstrate the bo oster response if they have a 
2-fold response (i.e., post -/pre-vaccination ≥ 2)  
 Seroprotection rates will be presented separately for dip htheria and 
tetanus as:  
• Proportion of subjects pre - and post-vaccination with anti -diphtheria 
antitoxin concentration ≥ 0.01,  ≥ 0.10, and ≥ 1.0 IU/mL  
 • Proportion of subjects pre - and post-vaccination with anti -tetanus 
antitoxin concentration ≥ 0.01, ≥  0.10, and ≥ 1.0 IU/mL  
 As an observational control,  pre-and post-vaccination GMCs and booster 
response rates  (for pertussis, diphtheria, and tetanus) , as well as 
seroprotection rates (for diphtheria and tetanus only) will also be 
calculated for adolescent, adult, and older adult subjects who receive 
BOOSTRIX®. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 16 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 17 of 71  Calculation of Sample Size  
Although there are no statistically powered hypotheses in this study, t he 
overall study cohort (N=1350) will provide a probability of approximately 
93% of observing any AE with a true incidence of 0.2%. For each 
formulation (N=225), there is a probability of approximately 95% of observing any AE with a true incidence of 1.3%, and a probability of approximately 36% of observing any AE with a true incidence of 0.2%.  
 Assuming a drop-out rate of approximately 10%, a total of 67 evaluable 
subjects per group are anticipated. 
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 17 of 72

[COMPANY_011] Pasteur ADC01 
Protocol Version 3.0  
Confidential/Proprietary Information  
Page 18 of 71 Table of Study Procedures  
Phase I/II Study, [ADDRESS_1266741]  
Visit (V)/Contact [CONTACT_4838] 1 (V01) Telephone Contact 
1(TC1) Visit 2 (V 02) Telephone 
Contact 2 (TC2) 
Study timelines (days)  D0 D8 D30 D180 
Time windows (days)   [+3 Days]  [+ 14 Days]* [+14 days]  
Informed consent form/Assent form (if applicable†) X    
CMI informed consent addendum form, as 
applicable X    
Inclusion/exclusion criteria  X    
Temperature  X    
Collection of demographic data  X    
Urine pregnancy test (if applicable)‡ X    
Verbal medical and vaccination history X    
Physical examination§ X    
Collection of Concomitant Therapy** X    
Measure circumference of both arms†† X    
Randomization/allocation of subject number  X    
Blood sampling (BL), approximately 10–20 mL‡‡ BL1  BL2  
Vaccination X    
Immediate surveillance (30 min)  X    
Diary card provided X    
Telephone contact§§  X   
Diary card collected and reviewed    X  
Collection of solicited injection site and systemic reactions   X  
Recording of unsolicited AEs  D0 to V02   
Memory aid provided***   X  
Recording of MAAEs†††   Visit 02 to TC2 
Recording of SAEs To be reported at any time during the study 
Follow-up telephone call‡‡‡    X 
Completion of 6 -month follow -up    X 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 18 of 72

[COMPANY_011] Pasteur ADC01 
Protocol Version 3.0  
Confidential/Proprietary Information  
Page 19 of 71 *For subjects in the CMI subset, the window will be [+ 7 Days].  
†Age of majority to follow state regulations 
‡For women of childbearing potential. The urine pregnancy test must be performed before vaccination. The pregnancy test must be 
negative for enrollment.  
§Targeted physical examination based on medical history. Temperature needs to be measured and recorded in the source 
documents. 
**As specified in  Section 6.7. 
††If the subject develops a Grade 3 solicited injection site (including ELS) or systemic reaction, the subject or subject’s 
parent/guardian is re quired to contact [CONTACT_29261]. The site must attempt for the subject to be seen at the study site within 
24 hours to assess the extent of the reaction.  
‡‡Collection of the baseline blood sample (BL1) before vaccination, approximately 10 mL. An add itional 10  mL will be collected 
for the CMI subgroup at each time point. 
§§This call to be made 8 to 10 days after the vaccination at V01. If D8 (+3 days) falls on a weekend or a holiday, the telephone call 
may be made on the following working day. During this call the staff will determine whether the subject experienced any SAE, 
Grade 3 solicited adverse reactions (including ELS) not yet reported, remind the subject or subject’s parent/guardian to cont inue to 
use the DC up to V02 and to bring the DC to the study center at V02, and will confirm  the date and time of V02.  
***The MA is used for recording any AEs between V02 and TC2.  
†††An MAAE that occurs between V01 and V02 will be r ecorded as unsolicited AEs.  
‡‡‡Staff will contact [CONTACT_35323]’s parent/guardian by [CONTACT_1381] 180 days (+14 days) after vaccination at V01 to 
identify the occurrence of any MAAEs and unreported SAEs for the period between V02 and TC2. 
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 19 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266742] of Abbreviations  
ap acellular pertussis (lower content)  
aP acellular pertussis (higher content)  
AE adverse event  
AR adverse reaction  
CDM Clinical Data Management  
CLC Clinical Logistics Coordinator  
CMI cell mediated immunity  
CRA Clinical Research Associate 
eCRF electronic case report form  
CTA clinical trial agreement  
CTL  Clinical Team Leader   
d reduced diphtheria toxoid  
D day 
DC diary card  
EDC electronic data capture  
ELISA enzyme linked immunosorbent assay  
ELS extensive limb swelling 
ESDR early safety data review  
FAS full analysis set  
FHA filamentous hemagglutinin  
FIM fimbriae types [ADDRESS_1266743] 
GCI Global Clinical Immunology  
GCP Good Clinical Practice 
GPV Global PharmacoVigilance  
IATA International Air Transport Association  
ICF informed consent for m 
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
IND investigational new drug (application)  
IRB Institutional Review Board  
IVRS interactive voice response system  
IWRS interactive web response system  
LCLS last contact,  last subject  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 20 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 21 of 71 LLT [MedDRA] lowest level term    
LLOQ lower limit o f quantification 
MA memory aid  
MAAE medically -attended adverse events  
MedDRA  Medical Dictionary for Regulatory Activities 
mL milliliter 
OG Operating Guidelines 
PPAS per-protocol analy sis set 
PRN pertactin 
PSO Product Safety Officer  
PT pertussis toxoid  
RMO Responsible Medical Officer  
SAE serious adverse event  
SafAS safety analysis set  
SMT safety management team  
T tetanus toxoid 
TMF trial master file 
ULOQ upper limit of quantif ication 
US [LOCATION_002]  
V Visit 
WHO World Health Organization  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 21 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266744] commonly found in soil (1). The disease is characterized by 
[CONTACT_86525], painful muscle contractions, accompanied by [CONTACT_180325], hyperreflexia, and 
increased autonomic stimulation of the affected body part(s). Complications associated with 
tetanus include laryngospasms, spi[INVESTIGATOR_903087], and hypertension (2). Tetanus 
occurs sporadically worldwide, but it is uncommon in developed countries, mainly because of immunization and hygienic precautions taken in the management of wound and surgical procedures. 
Diphtheria
 
Diphtheria is an acute infection caused by [CONTACT_903102] . The main site of 
infection is the upper respi[INVESTIGATOR_4352], characterized by a patch of grayish pseudomembrane 
surrounded by [CONTACT_2898]. Complications associated with diphtheria include airway obstruction, myocarditis, and paralysi s. The case -fatality rate runs as high as 30 –95%, particularly 
in the elderly, de spi[INVESTIGATOR_903088] (3).  
Pertussis
 
Pertussis (whoopi[INVESTIGATOR_202365]) is a highly contagious infectious disease of the respi[INVESTIGATOR_903089] . The illness is characterized by [CONTACT_903103], which 
may or may not be associated with the classic inspi[INVESTIGATOR_335721]. Although pertussis is most severe and complications are most frequent in children less than one year of age, pertussis can 
affect persons of any age (4). Antimicrobial therapy is effect ive in eradicating the organism from 
the respi[INVESTIGATOR_903090]; therefore, control of the disease has been based on vaccine 
prophylaxis  (5). 
1.[ADDRESS_1266745]  
The proposed updated Tdap vaccine, under evaluat ion in Study ADC01 , will include the same 
antigenic components as Adacel®. The investigational formulations differ from Adacel® primarily 
in the amount per dose of pertussis antigens pertussis toxoid ( PT), pertactin (PRN), and fimbriae 
types 2 & 3 ( FIM), and/or in the .  The selection of Tdap formulations to be 
evaluated in Study ADC01 was based on safety and immunogenicity data obtained with varying antigen concentrations in clinical trials conducted in different age groups, as well as data from a range of in vitro formulation and process development studies and animal immunogenicity evaluations. 
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 22 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 23 of 71 1.3 Potential Benefits and Risks  
1.3.1 Potential Benefits to Subjects  
Subjects in all groups will be vaccinated with either one of the four investigational Tdap 
formulations or a licensed Tdap vaccine (Adacel® or BOOSTRIX®) and will likely gain benefit 
against infectious disease through boosting of their immunity to diphtheria, tetanus and pertussis. 
1.3.2 Potential Risks to Subjects  
Based on safety data from prev ious trials  with similar products , potential risks of the study 
vaccines are limited to the usual injection site reactions expected following any injectable vaccine 
such as pain, redness and swelling. Fever may also occur but is general ly mild in intensity . 
Extensive Limb S welling (ELS) has been reported in a small proportion of individuals following 
vaccination with acellular pertussis vaccines and may be more common following booster doses. All these reactions resolve spontaneously, usually within a few days after vaccination.  
As with any vaccine, investigational Tdap vaccine formulations may not protect 100% of 
individuals against the diseases they are designed to prevent.  
The risks associated with blood drawing include injection site  pain, bruising, and (rarely) fainting 
or infection.  
Tdap is contraindicated in persons with known systemic hypersensitivity to any of their 
components or a history of life-threatening reaction to the vaccine or to a vaccine containing the 
same substances. Because of uncerta inty as to which vaccine component may be responsible, no 
further vaccination with the diphtheria, tetanus, or pertussis components found in Tdap should be carried out. 
Please see the Investigator Brochure for complete descriptions of the potential risks associated 
with Tdap vaccines.  
1.4 Rationale  for the Trial 
The overall goal of this Phase I/II Study is to select a formulation for further clinical development of SP0173 (Tetanus Toxoid [T], Reduced Diphtheria Toxoid [d] and Acellular Pertussis Vaccine Adsorbed [ap]) as a combination pertussis vaccine formulation (Tdap) to boost immunity towards 
the targeted diseases in individuals ≥ [ADDRESS_1266746] 
age. In subjects < 6 5 years of age, SP0173 antibody GMCs for T, d, and pertussis antigens will be 
compared with Adacel
®. In subjects ≥ 65 years of age SP0173 antibody GMCs for T and d will be 
compared with Adacel®, whereas antibody GMCs for pertussis antigens will be compared  with 
historical responses from the Sweden I (for filamentous hemagglutinin [ FHA], FIM, and PRN) 
and M5A10 (for PT)  (6) studies. The immunogenicity objectives of Study ADC01 are 
observational and therefore the study is not powered to detect statistically significant differences in antibody responses between candidate formulations or to assess non- inferiority to historical 
controls. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 23 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 24 of 71 Collectively , safety and immunogenicity data will be essential determinant s of the suitability of a 
candidate vaccine formulation for advancement to Phase III clinical development.  
2 Trial Objectives  
2.1 Observational Objectives 
Safety/Reactogenicity  
• To describe the safety profile of each SP0173 investigational formulation.  
Immunogenicity  
• To describe the immunogenicity of each SP0173 investigational formulation.  
The endpoints for the observational objectives  are presented in Section [IP_ADDRESS] and 
Section [IP_ADDRESS]. 
3 Investigators and Trial Organization 
This study will be conducted in approximately 20 centers in  the US. Details of the study centers 
and the Investigators at each center are provided in the “List of Investigators and Centers Involved 
in the Trial”  document. 
The safety of the investigational product will be continuously monitored by [CONTACT_903104] 3 types of surveillance: 
• Ongoing safety surveillance  of SAE. 
• Periodic safety surveillance (during enrollment and safety data collection for each of the 
2 sets of age co horts: adults followed by [CONTACT_903105]/older adults)  
 
• Early Safety data review  (ESDR), during which enrollment in the study (between age 
cohorts) will be paused.  
 
 
 
 
 
 
 
 
 
Immunogenicity testing will all be performed at the [COMPANY_011] Pasteur Global Clinical Immunogenicity (GCI) lab oratories in Swiftwater, PA, [LOCATION_003] . 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 24 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 25 of 71 The Sponsor’s Responsible Medical Officer (the person author ized to sign this protocol and any 
amendments on behalf of the Sponsor) is , , 
Clinical Team Leader (CTL) or such delegate as may be identified in her absence.   
4 Independent Ethics Committee/ Institutional Review Board 
Before the investigational product can be shipped to the investigational site and before the 
inclusion of the first subject, this protocol, the informed consent form (ICF), subject recruitment procedures, and any other written information to be provided to subjects must be approved by, and/or receive favorable opi[INVESTIGATOR_35269], the appropriate Independent Ethics Committee (IEC) or Institutional Review Board (IRB).  
In accordance with Good Clinical Practice (GCP) and local regulations, each Investigator and/or 
the Sponsor are responsible for obtaining this approval and/or  favorable opi[INVESTIGATOR_190579]. If the protocol is subsequently amended, approval must be re-obtained for each substantial amendment. Copi[INVESTIGATOR_35271], along with information on the type, version number, and date of document, and the date of approval, must be forwarded by [CONTACT_35321]/IRB (the names and qualifications of the 
members attending and voting a t the meetings).  
The Investigator will submit written summaries of the status of the trial to the IEC/IRB  annually, 
or more frequently if request ed. All SAEs  occurring during the trial that are related to vaccination  
will be reported by [CONTACT_903106]/IRB , according to the IEC/IRB policy. 
5 Investigational Plan 
5.1 Description of the Overall Trial Design and Plan  
5.1.1 Trial Design  
This will be a Phase I/II, randomized, modified double- blinded, multi-center, active comparator, 
multiple-formulation, dose ra nging, step-down study to assess the safety and immunogenicity of 
SP0173 in healthy adolescents, adults, and older adults conducted in the US. 
Subjects’ age groups are defined as follows:  
• Adolescents: age 10 –18 years  
• Adults: age 19–64 years  
• Older Adults: age ≥ [ADDRESS_1266747] s (450 subjects per age group). Within each age group 
subjects wil l be randomized in equal proportion to receive a single dose of SP0173 (1 of 
4 formulations), Adacel®, or BOOSTRIX® (Table 5.1). 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 25 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 26 of 71 Table 5.1: Study groups and vaccine formulations  
 
 
 
    
  
  
    
 
     
         
         
         
         
         
         
 
 
 
Subjects will be monitored for immediate unsolicited sys temic AEs for 30 mi nutes after 
vaccination. Solicited reactions (injection site and systemic) will be collected from Day  (D)[ADDRESS_1266748]-vacci nation. Unsolicited AEs will be collected from V01 (D0) to V02 (D30-D44) and 
SAEs will be collected throughout the study period from D0 through D180 after vaccination. 
Medically -attended adverse events ( MAAEs) will be collected throughout the s tudy from 
V01(D0) to V02(D30-D44) as part of the collection of unsolicited AE information and from 
V02 to the end of the 6-month follow-up (D180) as MAAEs. An MAAE  that occurs within the 
study period but meets the definition of an SAE should be reported as an SAE. All subjects will be asked to provide a blood sample for immunogenicity assessment at bas eline 
(pre-vaccination at V 01) and at V02. A su bset of subjects ( 36 adolescents, 60 adults and 60 older 
adults) enrolled in all groups will provide an additional pre - and post-vaccination blood sample 
for exploratory testing of parameters of cell- mediated immunity  (CMI). The results of that testing 
will be described in a separate report.  
5.1.2 Justification of the Trial Design  
The proposed Phase I/II study, ADC01, will be the first trial in humans to evaluate the different 
formulations of SP0173 (low-, middle- and high-dose) when adjuvanted to either  or 
 and administered to adolescent, adults and older adults, i.e. the key target age groups 
where administration of a tetanus, diphtheria and pertussis vaccine is recommended by [CONTACT_903107]. The dose of per tussis antigens to be 
explored in all age groups varies for the PT, PRN and FIM components and is the same in all formulations for the FHA component. 
The selection of investigational Tdap formulations to be evaluated in ADC01 was based on safety 
and immunogenicity data obtained with varying antigen concentrations in clinical trials conducted 
in different age groups, as well as data from a range of in vitro formulation and process 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 26 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 27 of 71 development studies and animal immunogenicity evaluations. The immunogenicity of each 
formulation is enhanced by [CONTACT_400406] .  
As a safety precaution, Study ADC01 will employ a step-down approach for enrollment: adult 
subjects (age 19 –64 years) will be enrolled and vaccinated, and an internal review of safety data 
collected through D 30 after injection will be conducted; an acceptable review of safety data and 
an acceptable safety profile based on prospectively defined criteria will be required before concurrent enrollment of adolescent (age 10–18 years)  and older adult subjects (age ≥ 65 years). 
5.1.3 Trial Plan  
Eligible subjects will be identified and enrolled  at each research center . Initially, enrollment will 
be restricted to the subjects in the adult age group (19 –64 years of age). Enrollment of adolescent 
and older adult subjects is planned subsequent to a satisfactory review of safety data from 
V01 through V02 post-vaccination for the adult age group.   
Each subject  and/or subjects’ parent/guardian  must sign and date the ICF (and assent form for 
subjects under the age of legal majority [according to state regulation] ) before any procedure or 
treatment associated with the study is performed.   
Subjects will receive one injection of either SP0173 vaccine, Adacel
®, or BOOSTRIX® on 
D0. Each subject will be asked to provide a blood sample (10–20 mL/bleeda) to be collected 
before vaccine injection at V01 (D0) and at V02 (30 days [± 14 daysb] after injection).  
All subjects and/or subjects’ parent/guardian  will be asked to record solicited injection  site 
reactions and solicited systemic reactions  that occur for 7 days after the injection and unsoli cited 
AEs that occur from V01(D0) through V0 2 (D30). SAEs will be collected throughout the study 
period from D0 through D180 after vaccination. MAAEs will be collected thro ughout the study 
from V01 through V0 2 (as part of the collection of unsolicited AEs) and from V02 through 
D180 (as MAAEs).  
5.1.4 Visit Procedures 
V01 (D0): Inclusion, Randomization, Applicable Blood Sample, and Vaccination  
1) Give the subject or subject’s parent/guardian information about the study. 
2) Obtain informed consent and assent (for subjects under the legal age of majority [according 
to state regulations ]) and answer any questions  to ensure that the subjects and/or subject’s 
parent/guardian have been informed of all aspects of the trial that are relevant to their 
decision to participate. Document the informed consent process in the subject’s record.  
                                                 
a  Most subjects will provide approximately [ADDRESS_1266749]-vaccination.  
b  For subjects in the CMI subset, the V 02 window will be between Day 30 and Day 37 . 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 27 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 28 of 71 3) Date and sign the ICF (and assent form  for subjects under the legal age of majority 
[according to state regulati ons]) after it has been signed and dated by [CONTACT_35323]’s 
parent/guardian. Retain the original and give a signed copy to the subject or subject’s 
parent/guardian. 
4) Check inclusion and exclusion criteria for eligibility. 
5) Collect demographic inform ation. 
6) For women of childbearing potentiala, obtain a urine pregnancy test. 
7) Obtain verbal medical  and vaccination history about the subject (including relevant prior and 
concomitant therapy). 
8) Perform and document a limited physical examination per standard site -specific 
immunization practices. If a routine physical examination was performed at the same clinical 
site no more than [ADDRESS_1266750]’s health 
status and update with a signature, noting review by [CONTACT_903108] a physical examination. Measure and record temperature. If the temperature is  
≥ 100.4°F, postpone vaccinations until the condition is resolved. 
9) Call the IVRS/IWRS for assignment of the subject number, randomization to study group, and allocation of the product to be administered (should be performed by [CONTACT_515311]).  
10) Obtain pre- vaccination  blood sample (see Section 7.1 f or detailed instructions regardin g the 
handling of blood samples).  
11) Instruct the subject or subject’s parent/guardian how to perform and record the arm circumference measurements. The subject or subject’s parent/guardian will be requested, under the supervision of the study staff, to perf orm the baseline measurement  of both arms. 
Record the circumference of both arms in  the source document and transcribe that of the 
vaccinated arm in the subject’s DC.  
12) Administer the study or control vaccine intramuscularly in the deltoid region of the arm. 
13) Keep the subject under observation for [ADDRESS_1266751] any adverse reaction in the source documents and electronic case report form (eCRF).  
14) Provide the DC  to the subject or subject’s parent/guardian  and ask them to record in it 
solicited injection site and systemic reactions for D0 to D7. Ask them to use the DC to record 
any unsolicited AEs (from V01 to V02) and concomitant medications. MAAE s that occur 
from V01 to V02 will be recorded as unsolicited AEs on the DC as part of the unsolicited 
AEs collected for this post-vaccination period. Provide appropriate training including ruler, 
measuring tapes, digital thermometer, and instructions for use. 
                                                
 
a  To be considered of non- childbearing potential, a female must be pre -menarche or post -menopausal for at least [ADDRESS_1266752] 4 weeks after vaccination.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 28 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 29 of 71 15) Instruct the subject or subject’s parent/guardian to expect a telephone c[INVESTIGATOR_2394]tact [INVESTIGATOR_2394] D8 post -
vaccination to identify the occurrence of any SAE , Grade 3 solicited adverse reactions 
(including ELS ) not yet reported and to remind him/her to complete the DC up to V0 2 and 
bring it back at V0 2. The date of the appointment for V02 will be confirmed. 
16) If the subject deve lops a Grade 3 solicited  injection site or systemic AE (see Table 9.1 and 
Table 9.2), develop significant change in arm  circumference (increased  ≥ 50 mm from 
pre-vaccination measurement at  baseline) , or ELS which occur during the 7-day period after 
vaccination, the subject or subject’s parent/guardian  is required to contact [CONTACT_573949] . The site staff must attempt for the subject to be seen at the study site within 
[ADDRESS_1266753] (or parent/guardian ) is to be instructed to take measurements of the 
vaccinated arm circumference, and record in the DC, until the swelling is resolved  (See 
Operating Guidelines [OG]  for details) . 
17) Set up an appointment for V0 2 (D30–D44) and instruct the subject or subject’s 
parent/guardian to bring the DC to the visit to discuss the information entered with the study 
personnel. 
Note: For subjects in the CMI subset, the V 02 window will be between D30 and D37 
18) Remind the subject or subject’s parent/guardian to notify the site in case of an SAE. 
19) Complete the relevant case report form ( eCRF) pages for this visit.  
Telephone Cal l 1 (D8 + 3 Days)  
Note: If D8 falls on a weekend or a holiday, the telephone call may be made on the following 
business day.  
1) Record relevant information concerning the subject’s health status on the telephone contact 
[CONTACT_982]. If an SAE, Grade 3 solicited adve rse reaction  (including ELS) has occurred, foll ow the 
instructions in  Section 10  for reporting it.  
2) Remind the subject or subject’s parent/guardian to do the following: 
• Continue to complete the DC, and bring it to V0 2. 
• Notify the site in case of an SAE . 
3) Confirm V0 2 appointment. 
V02 (window 30–44a days after V0 1): Collection of Safety Information and Blood Sample  
1) Collect the DC. Re view the pages of the DC with the subject or subject’s parent/guardian, 
including any AEs , concomitant medications, or therapy and medical visits that occurred 
since vaccination.   
2) Obtain the second blood sample (see  Section 7.1 for detailed instructions regarding the 
handling of blood samples). 
                                                 
a  For subjects in the CMI subset, the V 02 window will be between D30 and D 37 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 29 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 30 of 71 3) Give the subject or subject’s parent/guardian  a memory aid (MA)  and provide instructions for 
the MA completion. Inform them to expect the 6-month telephone follow-up. 
Telephone Call 2 (D180 +14 days)  
1) Review the MA  with the subject or subject’s parent/guardian. 
2) Record relevant information concerning the subject’s health status on the telephone contact 
[CONTACT_982]. If an SAE or MAAE  occurred, follow the instruction s in Section 10 fo r reporting it.  
3) Complete the relevant eCRF forms for this call, as well as the termination record in the eCRF. 
SAEs and AEs That Are Related to Vaccination or That Led to Discontinuation: 
At any time during the study, a subject who experiences an SAE or an AE must be followed if 
either of the following is true: 
• The SAE or AE is considered by [CONTACT_357271], and is not 
resolved by [CONTACT_357272]’s participation in the trial 
• The subject has been discontinued from the trial because of the SAE or AE 
Any such subject must be followed until the condition resolves, becomes stable, or becomes chronic. 
5.1.[ADDRESS_1266754] been obtained. 
Planned trial period - FVFS (first visit, first subject) to LVLS (last visit, last subject) : 
 Adult Subjects: Octo ber 2015–July 2016 
 Adolescent Subjects:  April 2016–April 2017 
 Older Adult Subjects: May  2016–March  2017 
Planned inclusion period - FVFS to  FVLS (first visit, last subject ): 
 Adult Subjects: Octo ber 2015–December 2015 
 Adolescent Subjects:  April 2016–Octo ber 2016 
 Older Adult Subjects: May  2016–Se ptember 2016 
Planned primary vaccination period: Please see dates for planned trial period  
Planned en d of trial
a: April 2017 
Planned date of final clinical study report: November [ADDRESS_1266755] i.e. 6 -month follow -up telephone call  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 30 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266756]  and any potential 
investigation(s). I f the risk for certain SP0173 formul ation(s) has been determined as high, 
enrollment of the next age groups (adolescents and older adults) for the respective formulation 
will not proceed.  
In addition to the ESDR, the usual and ongoing process of monitoring safety signals will continue unchanged (See  Section 3) . 
Apart from the ESDR  and the ongoing safety review, the study may be interrupted at any time if 
new data about the investigational product become available, and/or on advice of the Sponsor, the IEC/IRB, or the governing regulatory authorities in the US where the study is taking place.  
If the study is prematurely terminated or suspended, the Sponsor will promptly inform the 
Investigators, the IECs/IRBs, and the regulatory authorities of the reason for termination or suspension. If the study is prematurely terminated for any reason, the Investigator will promptly 
inform the study subjects/subjects’ parents/guardians and should assure appropriate therapy and follow-up. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 31 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 32 of 71 5.2 Enrollmen t and Retention of Trial Population  
5.2.1 Recruitment Procedures 
Subjects may be recruited from the general population. The site will ensure that any 
advertisements used to recruit subjects (informational brochures, letters, pamphlets, posters, and other advertisements) are submitted to [COMPANY_011] Pasteur prior to submission to the IRB for approval. 
5.2.[ADDRESS_1266757]  (or an adolescent subject and their 
parent/guardian) voluntarily confirms his or her willingness to participate in a particular trial. 
Informed consent must be obtained before any study procedures are performed. The process is 
documented by [CONTACT_3553] a written, signed, and dated ICF. 
For this study, in addition to the ICF that is signed by [CONTACT_423]'s parent/guardian, subjects that 
have not reached the legal age of majority (according to state regulations) will be asked to review 
and sign a separate informed assent form.  
In accordance with GCP, prior to signing and dating the consent  and assent  form, the subject  (or the 
adolescent subject and their parent/guardian) must be informed by [CONTACT_903109], and must have sufficient time and opportunity to ask any questions. 
The actual ICF  form used at each center may differ, depending on local regulations and IEC/IRB  
requirements. However, all versions must contain the standard information found in the sample 
ICF provided by [CONTACT_1034]. Any change to the content of the ICF must be approved by [CONTACT_29540]/IRB  prior to the form being used. 
If new information becomes available that may be relevant to the subject’s or the adolescent subject and their parent/guardian willingness to continue participation in the trial, this will be 
communicated to him/her in a timely manner. Such information will be provided via a revised ICF or an addendum to the original ICF. 
Informed consent forms will be provided in duplicate, or a photocopy of the signed consent/ assent 
will be made. The original will be kept by [CONTACT_737], and the copy will be kept by [CONTACT_285927]/or subject’s parent/guardian. 
Documentation of the consent process should be recorded in the source documents. 
In designated study sites, a convenience sample of 36 adolescents (10–18 years of age), 60 adults 
(19–64 years of age), and 60 older adults (≥ 65 years) will be invited to provide an additional 
blood sample for CMI testing. An addendum to the ICF will be prepared to request voluntary provision of an additional blood sample (approximately 10 mL ) for the test.  Prior to signing and 
dating the addendum, the subject (or the adolescent subject and their parent/guardian ) must be 
provided by [CONTACT_903110], and must have sufficient time and opportunity to ask any questions. A photocopy of the signed CMI addendum will be made and given to the subject. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 32 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266758] fulfill all of the following criteria in order to be eligible for trial enrollment:  
1) Aged 10 to 18 yearsa, 19 to 64 yearsb, or ≥ 65 yearsc on the day of inclusion. 
2) Informed consent form has been signed and dated by [CONTACT_423], or assent form has been 
signed and dates by [CONTACT_903111]/guardian. 
3) Subject or subject and parent/guardian  able to attend all scheduled visits and to comply with 
all study procedures. 
5.2.5 Exclusion Criteria  
An individual fulfilling any of the following criteria is to be excluded from trial enrollment: 
1) Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche or post- menopausal for at least [ADDRESS_1266759] 4 weeks after vaccination
d). 
2) Participation at the time of study enrollment (or in the 4 weeks preceding the study vaccination) or planned participation during the present study period in another clinical trial 
investigating a vaccine, drug, medical device, or medical procedure. 
3) Received any vaccine in the 4 weeks preceding the trial vaccination or planned recei pt of any 
vaccine betw een V01 and V02. For influenza vaccine only, defer if received in the 14-day 
period prior to enrollment or scheduled to receive in the 14-day period after enrollment. 
4) Known or suspected receipt of a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine, or Tdap-containing vaccine at any point in time, or receipt of a 
tetanus and diphtheria -containing vaccine in the precedi ng 5 years. 
5) Receipt of immune globulins, blood or blood-derived products in the past 3 months. 
                                                
 
a  “10 to 18 years” means from the day of the 10th birthday to the day before the 19th birthday 
b    “19 to 64 years” means from the day of the 19th birthday to the day before the 65th birthday  
c    “≥ 65 years” means from the day of the 65th birthday or ol der  
d    For pre-menarche females, the young female subjects will declare by [CONTACT_394291]. If a young female subject reaches menarche during the study, then she is to be considered as a woman of childbearing potential from that time forward.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 33 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 34 of 71 6) Known or suspec ted congenital or acquired immunodeficiency, immunosuppressive therapy 
such as anti -cancer chemotherapy or radiation therapy within the preceding 6 months, or 
long-term systemic corticosteroids therapy (prednisone or equivalent for more than 
[ADDRESS_1266760] 3 months). 
7) History of diphtheria, tetanus, or pertussis infection (confirmed either serologically or 
microbiologically). 
8) Known or suspected systemic hypersensitivity to any of the vaccine components or history of life-threatening reac tion to the study vaccine or a vaccine containing the same substances
a. 
9) Laboratory -confirmed / self -reported thrombocytopenia or bleeding disorder contraindicating 
IM vaccination . 
10) Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination . 
11) History of encephalopathy (e.g., coma, decreased level of consciousness, or prolonged seizures) not attributable to another identifiable cause within 7 days of administration of a previous dose of diphtheria and tetanus toxoids and pertussis (DTP), or diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. 
12) Deprived of freedom by [CONTACT_29511], or in an emergency setting, or hospi[INVESTIGATOR_29476]. 
13) Current alcohol abuse or drug addiction. 
14) Chronic illness that, in the opi[INVESTIGATOR_871], is at a stage where it might interfere 
with trial conduct or completion. 
15) Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness  (temperature ≥ 100.4°F). A prospective subject should not be 
included in the study until the condition has resolved or the febrile event has subsided. 
16) Identified as an Investigator or employee of the Investigator or study center with dir ect 
involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study. 
If the subject has a primary physician who is not the Investigator, the site—with the subject’s  
consent—must make a reasonable and timely attempt to contact [CONTACT_903112]/her of the subject’s participation in the study. In addition, the site should ask the primary  
physician to verify exclusion criteria relating to medical history and previous therapi[INVESTIGATOR_014] (such as 
receipt of previous vaccines, blood products, or immunosuppressive therapi[INVESTIGATOR_014]) . If contact [CONTACT_14599]’s primary physician is unsuccessful, the subject may still be en rolled in the study so long 
as the Investigator considers the subject eligible to participate (i.e., the subject meets all inclusion 
criteria and does not meet any exclusion  criteria). 
                                                
 
a  The components of SP0173 and comparator products are listed in Section 6.1 and in the Investigator’s Brochure.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 34 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266761] 
and ongoing. Any such conditions will be documented in the source document. Significant 
medical history (reported as diagnosis) including conditions for which the subject is or has been followed by a physician or conditions that could resume during the course of the study or lead to an SAE or to a repetitive outpatient care will be collected in the CRF. The significant medical 
history section of the CRF contains a core list of body systems and disorders that could be used to 
prompt comprehensive reporting, as well as space for the reporting of specific conditions and illnesses. 
For each condition, the data collected will be limited to:  
• Diagnosis (this is preferable to reporting signs and symptoms) 
• Presence or absence of the condition at enrollment 
The reporting of signs and symptoms is strongly discouraged. 
Dates, medications, and body systems are not to be recorded, and the information collected will not  
be coded. Its purpose is to assist in the later interpretation of safety data collected during the trial. 
5.2.7 Contraindications for Subsequent Vaccinations  
Not applicable since only one dose of vaccine will be administered in this trial. 5.2.8 Conditions for Withdrawal  
Subjects/Parents/ Guardians will be informed that they have the right to withdraw  themselves or 
their child  from the trial at any time.  A subject may be withdrawn from the study: 
• In any situation where, in the opi[INVESTIGATOR_689], continuation in the study would not 
be in the best interest of the subject due to safety concerns (withdrawal) without the subject’s 
permission  
• At the request of the subject (drop  out)  
The following will result in automatic withdrawal or exclusion of a subject from the study: 
• Significant non-compliance with the protocol, based on the Investigator’s judgment 
The reason for a withdrawal or dropout should be clearly documented in the source documents 
and on the CRF.  
The Investigator must determine whether voluntary withdrawal is due to safety concerns (in 
which case, the reason f or discontinuation will be noted as “SAE” or “other AE” as appropriate) 
or for another reason. 
Withdrawn subjects will not be replaced. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 35 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266762] to Follow- up Procedures  
In the case of subjects who fail to return for a follow-up examination, documented reasonable 
effort (i.e., documented telephone calls and certified mail) should be undertaken to locate or recall them, or at least to determine their health status while fully respecting their rights. These efforts should be documented in the CRF and in the source documents. 
5.2.[ADDRESS_1266763] significant (refer to the CRF completion guidelines for additional details and 
examples) : 
• Serious adverse event:  To be used when a subject drops out of or is withdrawn from the 
study by [CONTACT_190623], as defined in Section [IP_ADDRESS]. 
• Other adverse event:  To be used when a subject drops out of or is withdrawn from the study 
by [CONTACT_357277], as defined in 
Section [IP_ADDRESS]. 
• Non-compliance with protocol:  To be used when the Investigator withdraws a subject from 
the study because of failure to follow the protocol including when it is retrospectively 
discovered that a subject did not fulfill the eligibility criteria. The Investigator will provide a comment as to the specific cause of non -compliance.  
• Lost to follow -up: To be used when the Investigator withdraws a subject from the study 
because of failure to establish contact, as outlined in  Section 5.2.9. The Investigator will provide  
documentation that contact [CONTACT_188854] (i.e., return of unsigned certified letter recei pt). 
• Voluntary withdrawal not due to an adverse event:  To be used when a subject drops out of 
the study for any reason other than those listed above. 
5.2.[ADDRESS_1266764] will not be discontinued from the trial and wil l be followed for safety 
assessment (and may be followed for immunogenicity assessment, if applicable). 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 36 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266765] fill out a Pregnancy Reporting Form in the electronic data capture 
(EDC) system  and send it to the Sponsor within [ADDRESS_1266766] to obtain information about the outcome—
i.e., details about the delivery and the newborn, or about pregnancy termination—and must update the electronic Pregnancy Reporting Form. This information should be provided to the Sponsor 
within 1 month of delivery. 
Pregnancy itself is not considered an AE, but any complications during pregnancy are to be considered as AEs, and in some cases could be considered SAEs. Spontaneous abortions, fetal death, stillbirth, and congenital anomalies reported in the baby [CONTACT_35338], and the information should be provided to the Global PharmacoVigilance (GPV) Department 
regardless of when the SAE occurs (e.g., even after the end of the trial).  
5.3 Safety Emergency Call  
If, as per the Investigator's judgment, a subject experiences a medical emergency, the Investigator may contact [CONTACT_1034]'s Responsible Medical Officer (RMO) for advice on trial related medical question or problem. If the RMO is not available, then the Investigator may contact [CONTACT_29555]—available 24 hours a day, 7 days a week —that will forward all safety emergency  calls to 
the appropriate primary or back-up [COMPANY_011] Pasteur contact, as needed. The toll- free contact 
[CONTACT_903113].  
This process does not replace the need to report  an SAE. The investigator is still required to 
follow the protocol defined process for reporting SAEs to GPV (Please refer t o Section 10). 
In case of emergency code-breaking, the Investigator is required to follow the code-breaking procedures described in  Section 6.4.  
5.[ADDRESS_1266767] the earlier version. All substantial amendments (e.g., that affect the conduct of the trial or the safety of subjects)  
require IEC/IRB approval and must also be forwarded to regulatory authorities. 
An administrative amendment to a protocol is one that modifies some administrative or logistical 
aspect of the trial but does not affect its design or objectives or have an impact on the subjects’ 
safety. Regulatory authorities need only be notified about administrative changes. Administrative 
changes do not require IRB approval; however, the IRB must be notified whenever one is made. The Investigator is responsible for ensuring tha t changes to an approved trial, during the period 
for which IEC/IRB  approval has already been given, are not initiated without IEC/IRB  review and 
approval, except to eliminate apparent immediate hazards to subjects.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 37 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266768] resulting from this or 
any other trials become available; or for administrative reasons; or on advice of the Sponsor, the 
Investigators, and/or the IECs/IRBs. If the trial is prematurely termina ted or suspended, the 
Sponsor shall promptly inform the Investigators, the regulatory authorities, and the IECs/ IRBs of 
the reason for termination or suspension, as specified by [CONTACT_1214]. 
The Investigator shall promptly inform the trial subjects and assure appropriate therapy and/or 
follow-up for them. 
[ADDRESS_1266769] 
SP0173: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed 
(Tdap), [COMPANY_011] Pasteur Limited, Toronto, ON, Canada 
Form: Liquid solution 
Dose: 0.5 mL 
Route: IM 
Batch number: CD0097AA, CD0100AA, CD0102AA, CD0103AA 
[IP_ADDRESS] Composition  
Each 0.5 mL dose of vaccine contains the following components: 
 
      
      
 
        
        
    
     
       
 
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 38 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 39 of 71 [IP_ADDRESS] Preparati on and Administration  
SP0173 vaccine is a liquid preparation; as such, no diluent is required. After shaking, the vaccine 
is a white to off -white homogenous cloudy suspension. SP0173 vaccine should be administered as 
a single 0.5 mL injection by [CONTACT_903114], preferably in the deltoid region, using a 
needle not less than 1 inch (25 mm) in length. Before injection, the skin at the injection site should be cleansed  and prepared with a suitable germicide.  
Prior to administration, all study products must be inspected visually for cracks, broken seals, 
correct label content (see  Section 6.3.1),  and extraneous particulate matter and/or discoloration, 
whenever solution and container permit. If any of these conditions exists, the vaccine must not be administered. A replacement dose is to be used, and the event is to be reported to the Sponsor. 
Subjects must be kept under observation for 30 minutes after vaccination to ensure their safety, 
and any reactions during this period will be documented in the CRF. Appropriate medical equipment and emergency medications, including epi[INVESTIGATOR_238] (1:1000), must be available on site in the event of an anaphylactic or other immediate allergic reaction.  
[IP_ADDRESS] Dose Selection and Timing  
SP0173 vaccine will be administered to all Group 1 –[ADDRESS_1266770]  1 
Adacel
®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed 
(Tdap), [COMPANY_011] Pasteu r Limited, Toronto, ON, Canada 
Form: Liquid Solution 
Dose: 0.5 mL 
Route: IM 
Batch number:  C4774AA 
[IP_ADDRESS] Composition  
Each 0.5 mL dose of vaccine contains the following components: 
Active Ingredients  
Tetanus toxoid (T)     5 Lf 
Diphtheria toxoid (d)     2 Lf 
Acellular Pertussis  
 Pertussis toxoid (PT)     2.5 μg 
 Filamentous Hemagglutinin (FHA)  5 μg    Pertactin (PRN)    3 μg 
 Fimbriae Types 2 and 3 (FIM)  5 μg 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 39 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 40 of 71 Other Ingredients  
1.5 mg AlPO4 adjuvant (0.33 mg aluminum), 0.6% v/v 2-phenoxyethanol 
[IP_ADDRESS] Preparation and Administration  
The procedures for preparing and administering this control product are the same as those 
described for the trial product in Section [IP_ADDRESS] (7). 
[IP_ADDRESS] Dose Selection and Timing  
Adacel® will be administered to all Group [ADDRESS_1266771] 2 
BOOSTRIX®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellu lar Pertussis Vaccine, 
Adsorbed (Tdap), GlaxoSmithKline Biologicals, Rixensart, Belgium  and [COMPANY_001] Vaccines and 
Diagnostics GmbH (Marburg, [LOCATION_013]) 
Form: Liquid solution 
Dose: 0.5 mL 
Route: IM 
Batch number:  Commercial product to be supplied by [CONTACT_30107]. 
[IP_ADDRESS] Composition  
Each 0.5 mL dose of vaccine contains the following components: Active Ingredients:
 
Tetanus toxoid (T)     5 Lf 
Diphtheria toxoid (d)     2.5 Lf Acellular Pertussis  
 Pertussis tox oid (PT)    8 μg 
 Filamentous Hemagglutinin (FHA)  8 μg  Pertactin (PRN)    2.5 μg 
Other Ingredients: 
 
4.5 mg sodium chloride 
≤ 0.39 mg aluminum (aluminum oxyhydroxide adjuvant) 
≤ 100 µg residual formaldehyde 
≤ 100 µg polysorbate 80 (Tween 80) 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 40 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 41 of 71 [IP_ADDRESS] Preparation and Administration  
BOOSTRIX® will be prepared and administered according to manufacturer’s package insert  (8). 
[IP_ADDRESS] Dose Selection and Timing  
BOOSTRIX® will be administered to all Group [ADDRESS_1266772] Logistics  
6.3.1 Labeling and Packaging 
Primary packaging: Vial 
SP0173 will be supplied in single-dose vials with a clinical label. 
Adacel® will be supplied in single- dose vials with the manufacturer’s com mercial labeling 
retained on the vial. 
Outer packaging: Cardboard box 
SP0173 vials will be in individual cartons with a clinical label.  
Adacel® will be in individual cartons. 
BOOSTRIX® will be purchased by [CONTACT_903115]. 
6.3.[ADDRESS_1266773] Shipment, Storage, and Accountability  
[IP_ADDRESS] Product Shipment  
The Clinical Logistics Coordinator (CLC) will contact [CONTACT_29517] a designee in order to 
determine the dates and times of delivery of products.  
Each vaccine shipment will include a temperature-monitoring device to verify maintenance of the 
cold chain during transit. On delivery of the product to the site, the person in charge of product receipt will follow the instructions given in the OG, including checking that the cold chain was maintained during shipment (i.e., verification of the temperature recorders). If there is an indication that the cold chain was broken, this person should immediately quarantine the product, alert the [COMPANY_011] Pasteur  representative, and request authorization from [COMPANY_011] Pasteur  to use the 
product. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 41 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 42 of 71 [IP_ADDRESS] Product Storage  
The Investigator will be personally responsible for product management or will designate a staff 
member to assume this responsibility.  
At the site, products must be kept in a secure place with restricted access. Vaccines will be stored in a refrigerator at a temper ature ranging from +2°C to +8°C. The vaccines must not be frozen. 
The temperatur e must be monitored and documented (see the OG) for the entire time that the 
vaccine is at the trial site. In case of accidental freezing or disruption of the cold chain, vaccines must not be administered and must be quarantined, and the Investigator or authorized designee should contact [CONTACT_35340].  
[IP_ADDRESS] Product Accountability  
The person in charge of product management at the site will maintain records of product delivery 
to the trial site, product in ventory at the site, the unique dosing number (IVRS kit number) given 
to each subject, and the disposal of or return to the Sponsor of unused doses. 
The necessary information on the product labels is to be entered into the source document and the 
eCRF. 
The Sponsor’s monitoring staff will verify the trial site’s product accountability records against the record of administered doses in the CRFs and the communication from the IVRS/ IWRS (if 
applicable). 
In case of any expected or potential shortage of product during the trial, the Investigator or an 
authorized designee should alert the [COMPANY_011] Pasteur representative as soon as possible, so that a shipment of extra doses can be arranged.  
6.3.3 Replacement Doses 
If a replacement dose is required (e.g., because the vial broke or parti culate matter was observed in 
the vial), the site personnel must either contact [CONTACT_21926]/IWRS  to receive the new dose allocation, 
or follow the instructions given in the OG. 
6.3.[ADDRESS_1266774] accountability will be verified throughout the trial period. 6.3.5 Recall of Products  
If the Sponsor makes a decision to launch a retrieval procedure, the Investigators will be informed 
of what needs to be done. 
6.4 Blinding and Code -breaking Procedures  
As the presentation of the investigational and control vaccines differs, an observer-blinded procedure will be followed in the study, so that neither the Investigator (who is in charge of the 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 42 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 43 of 71 safety assessment), nor the subject‘s or the subject’s parent/guardian , nor the Sponsor will know 
which vaccine has been administered. The product preparation and administration, and the 
assessment of safety will be performed by 2 different individuals in 2 different rooms. 
The Investigator or delegate will include the subjects and will evaluate the safety during the 
30 minute period after each vaccination, but will not be aware of which vaccine (investigational or control) has been administered (i.e., the Investigator will be a blinded observer for safety). 
The blinded staff members, including the Investigator responsible for safety assessment, will not 
attend the vaccination session. However, they will remain available in case of emergency  (e.g., anaphylactic shock). 
The vaccinator (unblinded vaccine administrator) will prepare and administer the vaccine in a 
separate room, according to the IVRS/IWRS  subject treatment allocation.  
Product accountability forms will be kept in a secure place to which only the unblinded vaccine administrator in charge of vaccination has access. The Sponsor’s monitoring staff in charge of product management will be unblinded to the randomization. 
Emergency unblinding will be managed by [CONTACT_21926]/IWRS , using the dose number. 
The code may be broken by [CONTACT_357279]. Code-breaking should be limited, as far as possible, to the subject experiencing the SAE. If tim e allows, every effort should be 
made to discuss with the Sponsor RMO before unblinding the subject. 
The blind can be broken by [CONTACT_29517] a sub- investigator (medical doctor only
a), by 
[CONTACT_903116]/IWRS  system as explained in the code-breaking procedures described in the OG. 
Once the emergency has been addressed by [CONTACT_779], the Investigator must notify the [COMPANY_011] 
Pasteur RMO if a subject’s code was broken. All contact [CONTACT_903117].  
A request for the code to be broken may be made: 
• by [CONTACT_903118] E2A. In this case, the code will be broken only for the subject in question. The 
information re sulting from code-breaking (i.e., the subject’s vaccine or group assignment) will 
not be communicated to either the Investigator or the immediate team working on the study, except for the GPV representative.  
The IEC/IRB  must be notified of the code- breaking. All documentation pertaining to the event 
must be retained in the site’s study records and in the [COMPANY_011] Pasteur  files. Any intentional or 
unintentional code-breaking must be reported, documented, and explained, and the name [CONTACT_29562]. 
                                                
 
a  according to local regulations.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 43 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266775] who meets the eligibility criteria and signs an informed consent form will be 
randomly assigned to 1 of 6 groups via an IVRS/IWRS  Site. Unblinded s ite staff will call the 
IVRS/IWRS , enter identification and security information, and confirm a minimal amount of data 
in response to IVRS/IWRS  prompts. The IVRS/IWRS  will then state the subject number and the 
group subset, and have the caller confirm this. Subject numbers will be recorded on the eCRFs. 
The full detailed procedures for randomization are described in the OG.  
Subject numbers will be [ADDRESS_1266776] numbers should not  be reassigned for any reason.  
6.6 Treatment Compliance  
The following measures will ensure that the vaccine doses administered comply with those planned, 
and that any non- compliance is documented so that it can be accounted for in the data analyses:  
• All vaccinations will be administered by [CONTACT_357283] 
• The person in charge of product management at the site will maintain accountability records 
of product delivery to the trial site, product inventory at the site, dose given to each subject, and the disposal of unused or wasted doses 
6.7 Concomitant Medications  and Other Therapi[INVESTIGATOR_35274], ongoing medications including other therapi[INVESTIGATOR_014] e.g., vaccines, blood 
products, should be recorded in the source document as well as new medications prescribed for new medical conditions/AEs during trial participation.  
Documentation in the CRF of concomitant medication will be limited to specific categories of 
medication of interest beginning on the day of vaccination. This may include medication s of 
interest that were started prior to the day of vaccination. 
Reportable medications  will be collected in the eCRF from the day of vaccination to the end of 
the solicited and unsolicited follow-up period (e.g., 30 day safety follow- up) as they may impact 
the response to the vaccination and impact the consistency of the information collected on 
concomitant medications at any vaccination.  
The “reportable” medications are distributed according to two categories. These are:  
• Category 1 antipyretics, analgesics, non- steroidal anti-inflammatory drugs, corticosteroid s, 
and other immune modulators.  
Note: inhaled and topi[INVESTIGATOR_357242]. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 44 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 45 of 71 • Category 2: Other reportable medications as specified in the protocol (i.e., medications related 
to exclusion criter ia [please refer to  Section 5.2.5] and contraindications, if not captured as 
Category 1 medications) and other medications as noted here. All non-study vaccines, 
immune globulins, and blood or blood-derived products are included in this category. 
The information reported in the e CRF for each reported medication will be limited to:  
• Trade name 
• Given as treatment or as prophylaxis 
• Medication category  
• Start and stop dates  
(Note: prophylaxis is defined as medication taken to prevent any AEs that may occur following the administration of the study vaccine during the solicited follow-up period.) 
Dosage and administration route will not be recorded. Homeopathic medication will not be 
recorded. Topi[INVESTIGATOR_2855] t reatment will not be recorded. 
The fact that a medication was given in response to an AE will be captured in the “Action Taken” 
column of the AE only. No details will be recorded in the concomitant medication module of the CRF unless  the medication received belongs to one of the prelisted categories. Medications will 
not be coded. 
7 Management of Samples  
Blood samples for the assessment of antibody responses and cellular immunity analysis will be 
collected at V01 and at V02. See the Table of Study Procedures and Section 5.1.3 f or details of 
the sampling schedule. 
7.1 Sample Collection  
7.1.1 Serum Samples  
At V01 and V02, approximately 10 mL of blood (or approximately 20 mL of blood for subjects in the CMI subset)  will be collected in tubes provided by [CONTACT_903119]. 
Immediately prior to the blood draw, the staff member performing the procedure will verify the subject’s identity; will write the assigned subject's  number on the pre- printed label that contains 
that subject’s number and the sampling stage; and will attach the label to the tube. Blood is to be taken from the limb opposite to the one that will be used for vaccination. 
7.1.2 Blood Samples for Cellular Immunity Assessment  
Blood samples for c ellular immunity assessment will be collected at V 01 and V02. Samples 
(approximately 10 mL) will be collected in heparinized plastic tubes and will then be processed 
for cell isolation and freezing. Labeling will be done according to the procedure described in the 
OG for CMI testing . 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 45 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 46 of 71 7.2 Sample Preparation  
7.2.1 Serum Samples  
Detailed instructions on how to prepare blood samples for assessment of antibody response are 
contained in the OG provided to the site. An overview of the procedures is provided here. 
Following the blood draw, the tubes are to be left undisturbed, positioned vertically and not 
shaken, for a minimum of 1 hour and a maximum of 24 hours in order to allow the blood to clot. Samples can be stored at room temperature for up to 2 hours; beyond [ADDRESS_1266777] be refrigerated at a temperature of +2°C to +8°C after the period of clotting at room temperature and 
must be centrifuged within a maximum of [ADDRESS_1266778]’s number and the sampling stage or visit number.  
The subject’s number and the date of sampling, the number of aliquots obtained, the date and time 
of preparation, and the subject’s consent for future use of his / her samples are to be specified on a 
sample identification list and recorded in the source document. Space is provided on this list for 
comments on the quality of samples. 
7.2.2 Blood for Cellular Immunity Assessment  
Blood for cellular immunity analysis will be collected in BD Vacutainer
® Plus plastic plasma 
tube, light green BD Hemogard™ closure. Samples should not be centrifuged  and should be kept 
at room temperature. Labeling will be done according to the procedure described in the OG for 
CMI testing. Details on sample handling will be provided in the OG. 
7.3 Sample Storage and Shipment  
During storage, serum tubes are to be kept in a freezer whose temperature is set and maintained at 
-20°C or below. The temperature will be monitored and documented on the appropriate form during the entire trial. If it rises above -10°C for any period of time, the CLC must be notified. 
See the OG for further details.  
Shipments to the laboratories  will be made only after appropriate monitoring, and following 
notification of the CL C. Sera will be shipped frozen, using dry ice to maintain them in a frozen 
state, in the packaging container provided by [CONTACT_21440] . Again, temperatures will be monitored. 
Shipments must be compliant with the International Air Transport Association (IATA) 602 regulations. 
Samples will be shipped to Global Clinical Immunology (GCI) at [COMPANY_011] Pasteur . The address is 
provided in the OG.  The whole- blood sample for cellular immunity analysis will be stored at room temperature, and 
will be transported to the designated CMI laboratory  within the next 8 hours after collecting the 
sample. The address is provided in the OG. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 46 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 47 of 71 7.4 Future Use of Stored Serum /Blood Samples for Research 
Any unused part of the serum / blood samples will be securely stored at the [COMPANY_011] Pasteur GCI 
laboratory for a  minimum of [ADDRESS_1266779]’s parent/guardian will be asked to indicate in the ICF whether they will 
permit the future use of any unused stored serum samples for other tests. If they refuse 
permission, the samples will not be used for any testing other than that direc tly related to this 
study. If they agree to this use, they will not be paid for giving permission. (Anonymity of samples will be ensured.) The aim of any possible future research is unknown today, and may not 
be related to this particular study. It may be to improve the knowledge of vaccines or infectious 
diseases, or to improve laboratory methods. Genetic tests will never be performed on these samples with out individual informed consent. 
8 Clinical Supplies  
[COMPANY_011] Pasteur will supply the trial sites with protocols, ICFs, Assent forms, Addenda for CMIs, 
CRFs, SA E reporting forms, diary cards, memory aids, and other trial documents, as well as with 
the following trial materials: all study vaccines and injection materials, blood collection tubes, cryotubes, cryotube storage boxes, cryotube labels, temperature recorders, shippi[INVESTIGATOR_35275], 
rulers, and digital thermometers.  
The means for perf orming EDC will be defined by [CONTACT_35346] . If a computer is provided by 
[CONTACT_35346] , it will be retrieved at the end of the trial.  
The Investigator will supply all vaccination supplies, phlebotomy, and centrifugation equipment, including biohazard and/or safety supplies. The biohazard and safety supplies include needles and syringes, examination gloves, laboratory coats, sharps disposal containers, and absorbent countertop paper. The site will ensure that all biohazard wastes are autoclaved and disposed of in accordance with local practices. The Investigator will also supply appropriate space in a temperature -monitored refrigerator for the storage of the products and for the blood samples, and 
appropriate space in a temperature -monitored freezer for serum aliquots. 
In the event that additional supplies are required, study staff must contact [CONTACT_35346] , 
indicating the q uantity required. Contact [CONTACT_903120] . They must allow 
approximately [ADDRESS_1266780] the supplies sent to their site. 
9 Endpoints and Assessment Methods  
9.1 Primary Endpoints and Assessment Methods  
9.1.1 Safety 
There are no primary objectives for safety.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 47 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 48 of 71 9.1.2 Immunogenicity  
There are no primary objectives for immunogenicity. 
9.1.3 Efficacy 
No clinical efficacy data will be obtained in the trial.  
9.2 Secondary Endpoints and Assessment Methods  
There are no secondary objectives in this study. 
9.2.1 Safety 
There are no secondary objectives for safety.  
9.2.2 Immunogenicity  
There are no secondary objectives for immunogenicity. 9.2.3 Efficacy 
No clinical efficacy data will be obtained in the trial.  
9.3 Observational Endpoints and Assessment Methods  
9.3.1 Safety 
[IP_ADDRESS] Safety Definitions  
The following definitions are taken from the ICH E2A Guideline for Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting. 
Adverse Event (AE):  
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.  
Therefore an AE may be:  
• A new illness  
• The worsening of a concomitant illness 
• An effect of the vaccination, including the comparator 
• A combination of the above 
All AEs include serious and non- serious AEs.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 48 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 49 of 71 Surgical procedures are not AEs; they are the action taken to treat a medical condition. It is the 
condition leading to the action taken that is the AE (if it occurs dur ing the trial period).  
Pre-existing medical conditions are not to be reported as AEs. However, if a pre- existing 
condition worsens in frequency or intensity, or if in the assessment of the treating physician there 
is a change in its clinical significance, this change should be reported as an AE (exacerbation). 
This applies equally to recurring epi[INVESTIGATOR_35276]-existing conditions (e.g., asthma) if the frequency or intensity increases post-vaccination. 
Serious Adverse Event (SAE):  
Serious and severe are not synonymous. The term severe is often used to describe the intensity of 
a specific event as corresponding to Grade 3. This is not the same as serious which is based on 
patient/event outcome or action criteria usually associated with events that pose a threat to a 
patient’s life or functioning. Seriousness, not severity, serves as a guide for defining regulatory reporting obligations. 
An SAE is any untoward medical occurrence that at any dose  
• Results in death  
• Is life-threatening
a 
• Requires inpatient hospi[INVESTIGATOR_903091] 
• Results in persistent or significant disability / incapacityc 
• Is a congenital anomaly / birth defect  
• Is an important medical eventd 
Adverse Reaction:  
All noxious and unintended responses to a medicinal product related to any dose should be 
considered adverse reactions (AR).  
                                                 
a  The term “life -threatening” refers to an event in which the subject  was at risk of death at the time of the event; it 
does not refer to an event which hypothetically might have caused death if it were more severe.  
b  All medical events leading to hospi[INVESTIGATOR_892036], with the 
exception of: hospi[INVESTIGATOR_892037] -patient treatment with no 
hospi[INVESTIGATOR_059].  
c  “Persistent or significant disability or incapacity” means that there is a substantial disruption of a person’s ability 
to carry out normal life functions.  
d  Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately life -threatening or result in death 
or hospi[INVESTIGATOR_892038]. These should also usua lly be considered serious. Examples of such 
events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse, new onset diabetes, or autoimmune disease . 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 49 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 50 of 71 (The phrase “responses to a medicinal product” means that a causal relationship between a 
medicinal product and an AE is at least a reasonable possibility)  
Unexpected Adverse Reaction (U AR): 
An unexpected adverse reaction is an AR, the nature or severity of which is not consistent with 
the applicable product information (e.g., Investigator’s Brochure for an unapproved investigational medicinal product).  
The following additional definitions are used by [CONTACT_35346]: 
Solicited Reaction:  
A solicited reaction is an event that is prelisted  in the CRF. The assessment of these AEs post -
vaccination is mandatory. A solicited reaction is defined by a combination of: 
• Symptom and  
• Onset post- vaccination 
e.g., injection site pain between D0 and D7 post-vaccination, or headache between D0 and D7. 
A solicited reaction is therefore an AR observed and reported under the conditions (symptom and 
onset) prelisted (i.e., solicited) in the CRF and considered a s related to vaccination.  
Unsolicited AE/ AR: 
An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset post-vaccination, i.e., excluding solicited reactions, e.g., if headache between D 0 and D7 is a solicited reaction (i.e., prelisted in the CRF), then a headache 
starting on D7 is a solicited reaction, whereas headache starting on D8 post-vaccination is an unsolicited AE.  
An unsolicited non-serious AE is an unsolicited AE excluding SAEs. 
Injection Site Reaction:  
An injection site reaction
a is an AR at and around the injection site. Injection site reactions are 
commonly inflammatory reactions.  Systemic AE:  
Systemic AEs are all AEs that are not injection site reactions. They therefore include systemic 
manifestations such as headache, fever, as well as localized or topi[INVESTIGATOR_394280], e.g., erythema that is localized but that is not at the injection site. 
                                                
 
a  All injection site AEs are considered to be related to vaccination  and are therefore all injection site reactions . 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 50 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 51 of 71 Medically Attended Adverse Event s (MAAEs) 
An MAAE  is defined, for the purpose of this study, as a new onset of a condition that prompts the 
subject or subject’s parent/guardian to seek unplanned medical advice at a physician’s office or 
Emergency Department. This definition excludes pre-planned medical office visits for routine 
pediatric check -ups or follow-up visits of chronic conditions with an onset prior to entry in the 
study. Physician contact [CONTACT_357288] a physician office visit for the purpose of MAAE collection.  
[IP_ADDRESS] Safety Endpoints  
• Occurrence, nature (Medical Dictionary for Regulatory Activities [MedDRA] preferred term), duration, intensity, action taken, and relationship to vaccination of any unsolicited systemic AEs reported in the 30 minutes after vaccination.  
• Occurrence, time to onset, number of days of occurrence, action taken, and intensity of solicited (prelisted in the subject DC  and eCRF) injection site reactions and systemic reactions 
occurring through D7 after vaccination. 
• Occurrence, na ture (MedDRA preferred term), time to onset, duration, intensity, action taken, 
and relationship to vaccination (for systemic AEs only) of unsolicited (spontaneously reported) AEs occurring from vaccinatio n through 30 days after vaccination . 
• Occurrence, na ture (MedDRA preferred term), time to onset, duration, intensity, seriousness 
criteria, relationship to vaccination, and outcome of SAEs from V01 to 6-month follow-up for all groups after vaccination. 
• Occurrence, nature (MedDRA preferred term), time to onset, duration, intensity, seriousness criteria, relationship to vaccination, and outcome of MAAE s from V02 to the 6-month follow-
up for all groups after vaccination. 
[IP_ADDRESS] Safety Assessment Methods 
At V02, the Investigator or a delegate will ask the subject or su bject’s parent or guardian about 
any solicited reactions and unsolicited AEs recorded in the DC , as well as about any other AEs 
that may have occurred since the previous visit. All relevant data will be transcribed into the eCRF according to the instructio ns provided by [CONTACT_1034].  
[IP_ADDRESS].[ADDRESS_1266781]-vaccination surveillance should be documented in the source document. Any A E that 
occurs during this period will be noted on the source document and recorded in the e CRF, as 
follows: 
• Any unsolicited systemic AE occurring during the first [ADDRESS_1266782]- vaccination will 
be recorded on the e CRF as immediate unsolicited systemic AE .  
• Solicited and unsolicited injection site reactions and solicited systemic reactions will be 
recorded and analyzed as starting on the day of vaccination.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 51 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 52 of 71 • Any SAE occurring during the first [ADDRESS_1266783] as any other SAE and to the Sponsor, according to the procedures described in 
Section 10.  
[IP_ADDRESS].2 Reactogenicity (Solicited Reactions From Day  0 to Day 7 After Vaccination) 
After vaccination, subjects or subjects’ parents/ guardians will be provided with a safety DC, a 
digital thermometer, measuring tape and a flexible ruler, and will be instructed how to use them. 
The following items will be recorded by [CONTACT_903121] 7 days (i.e., D0 to D7) until resolution: 
• Daily temperature, with the route by [CONTACT_35350]  
• Daily measurement or intensity grade of all other solicited injection site and systemic 
reactions 
• Action taken for each event, if any (e.g., medication)  
The action taken by [CONTACT_29159]’s parents/guardians to treat any solicited reactions 
will be classified in the eCRF using the following scale: 
0: None 
1: Medication (self -medication with an existing prescription or over- the-counter medication) 
2: Health care provider contact (no new medication prescribed)  
3:  Health care provider contact [CONTACT_190638] a new medication (health care provider 
instructed subject to take a new medication, either an over -the-counter medication or one 
requiring a written prescription)  
4: Hospi[INVESTIGATOR_059] (inpatient) 
Subjects or subjects’ parents/ guardians will be contact[CONTACT_5143] 8 days after vaccination to 
identify the occurrence of any SAE , Grade 3 solicited adverse reaction s (including ELS) not yet 
reported and to remind them to record all safety information in the DC up to V02 and to bring the 
DC back to V02. The date of the appointment for V02 will be confirmed. 
If the timing of the telephone call should fall on a weekend or a holiday, the call should be made 
on the next business day. If contact [CONTACT_875045], study staff will continue calling until contact [CONTACT_58661]. Every telephone attempt and its outcome will be documented in the source document. 
Table 9.1 and Table 9.2 present, respectively, the injection site reactions and systemic reactions 
that are prelisted in the DCs and CRF, together with the intensity scales. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 52 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 53 of 71 Table 9.1: Solicited injection site reactions  : terminology, definitions, and intensity scales  
CRF term 
(MedDRA  
lowest level 
term 
[LLT]) Injection site 
pain Injection site 
erythema  Injection site 
swelling Upper limb edema Extensive swelling 
of the vaccinated 
limb 
Diary card term Pain
* Redness* Swelling* Change in limb 
circumference* Extensive limb 
swelling* 
Definition   Presence of a redness 
including the 
approximate point of needle 
entry Swelling at or near 
the injection site  
Swelling or edema is caused by a fluid 
infiltration in tissue 
or cavity and, depending on the 
space available for 
the fluid to disperse, swelling may be 
either soft 
(typi[INVESTIGATOR_897]) or firm (less typi[INVESTIGATOR_2855]) to 
touch and thus can 
be best described by 
[CONTACT_903122] -
vaccination 
measurement of the 
same arm  Swelling of the 
injected limb 
including the 
adjacent joint (i.e., elbow and/or 
shoulder) as 
compared to baseline. 
Intensity scale* Grade 1: No 
interference with activity  
Grade 2: 
Some interference 
with activity  
Grade 3: 
Significant; 
prevents daily activity  Grade 1: ≥ 25 to 
≤ 50 mm 
Grade 2: ≥ 51 to 
≤ 100 mm 
Grade 3: > 100 
mm Grade 1: ≥ 25 to 
≤ 50 mm 
Grade 2: ≥ 51 to 
≤ 100 mm 
Grade 3: > 100 mm Grade 1: > 0 to  
< 25 mm increase over pre-
vaccination 
measurement 
Grade 2: ≥ 25 to  
< 50 mm increase 
over pre-
vaccination 
measurement 
Grade 3: ≥  50 mm 
increase over pre-
vaccination measurement Not applicable‡  
* If any Grade 3 solicited injection site reaction (including ELS) is present, the subject or subject’s parent/guardian 
will be instructed to call the site  immediately. See procedure in  Section 5.1.4. 
† For the subjective reaction of pain, subjects or subject ’s parent/guardian  will record the intensity level (Grade 1, 2, 
or 3) in the DC. For the measurable reactions of redness, limb circumference, and swelling, they will 
record just the size of the reaction, and the classification, as Grade 1, 2, or 3 will be assigned by [CONTACT_160295].  
‡ By [CONTACT_559], ELS is considered as severe.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 53 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 54 of 71 Table 9.2: Solicited systemic reactions: terminology, definitions, and intensity scales  
CRF term 
(MedDRA 
lowest level 
term [LLT]) Fever Headache  Malaise Myalgia 
Diary card term Temperature* Headache * Feeling unw ell* Muscle aches and 
pains* 
Definition  Elevation of temperature to 
≥ 100.4°F Pain or discomfort in the head or scalp. Does not include migraine.  General ill feeling.  
Malaise is a generalized feeling of 
discomfort, illness, or 
lack of well -being that 
can be associated with 
a disease state. It can 
be accompanied  by a 
sensation of exhaustion 
or inadequate energy to 
accomplish usual activities.  Muscle aches and pains are common and can involve more than one muscle at the same 
time. Muscle pain can 
also involve the soft tissues that surround 
muscles. These 
structures, which are 
often referred to as 
connective tissues, 
include ligaments, tendons, and fascia 
(thick bands of 
tendons). 
Does not apply to 
muscle pain at the 
injection site which 
should be reported as injection site pain.  
Intensity scale** Grade 1: ≥ 100.4°F to 
≤ 101.1°F  
Grade 1: No interference with activity  
Grade 2: Some interference with activity  
Grade 3: Significant; prevents daily activity   Grade 2: ≥ 101.2°F to 
≤ 102.0°F 
 Grade 3: ≥ 102.1°F 
*If any Grade [ADDRESS_1266784]’s parent/ guardian will be instructed to 
call the site immediately . See procedure in  Section 5.1.4. 
**For all reactions but fever, subjects or subject’s parent/guardian will record the intensity level (Grade  1, 2, or 3) in 
the DC. For fever, they will record the body temperature, and the classification as Grade  1, 2, or 3 will be assigned 
at the time of the statistical analysis.  
 
Important notes for the accurate assessment of temperature:  
Subjects or subjects’ parents/ guardians are to measure body temperature once per day, preferably 
always at the same time. The optimal time for measurement is the evening, when body temperature is the highest. Temperature is also to be measured at the time of any apparent fever. The observed daily temperature and the route of measurement are to be recorded in the DC, and the highest temperature will be recorded by [CONTACT_29558]. The preferred route for measuring body temperature in this trial is  the oral route. Pre-vaccination temperature is also systematically 
collected by [CONTACT_903123] e source document. Tympanic thermometers must not be used.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 54 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 55 of 71 Important notes for the accurate measurement of limb circumference:  
Study personnel will instruct the subject (or subject and their parent/guardian) how to perform and 
record the limb circumference measurements using the measuring tape and measuring horizontally at the level of the axilla . The subject will be requested, under the supervision of the 
study staff, to perform the baseline measurement of both arms with the staff, immediately before 
immunization (baseline measurement)  at V01. The circumference of both arms will be recorded in 
the source document and that of the vaccinated arm will be transcribed in the subject’s DC. The 
measurement of the vaccinated arm will be recorded daily by [CONTACT_35323]’s parent/guardian in the DC. 
If the subj ect develops Grade 3  change in limb circumference ( ≥ 50 mm over pre-vaccination 
measurement at baseline) or ELS
a (soft tissue swelling that occurs post -vaccination and extends 
from the injection site to involve an adjacent joint [e.g. the elbow, shoulder joint, or both] ) which 
occur during the 7-day period after vaccination, the subject (or parent/guardian ) is required to 
contact [CONTACT_29261] . The site must attempt to arrange for the subject to be seen at the 
study site within [ADDRESS_1266785] (or parent /guardian) is 
to be instructed to take measurements of the vaccinated limb circumference and record in the DC 
until the swelling is resolved  (See OG for details). 
[IP_ADDRESS].3 Unsolicited Non -serious Adverse Events From D 0 to V02 After Vaccination 
In addition to recording solicited reactions,  subjects or subjects’ parents/guardians will be 
instructed to record any other medical events that may occur  between V01 and V02. Space will be 
provided in the DC for this purpose. For each unsolicited non- serious AE, the following 
information is to be recorded: 
• Start and stop datesb  
• Intensity of the event: 
• For measurable unsolicited non-serious AEs that are part of the list of solicited reactions, 
the size of the AE as well as the temperature for fever will be collected and analyzed 
based on the corresponding scale used for solicited reactions  (see Table 9.1 and
 Table 9.2). 
                                                 
a  Regardless of the arm circumference measurements and differences, if in the subject’s or su bject and their 
parent/guardian opi[INVESTIGATOR_903092] [ADDRESS_1266786] an d their parent/guardian is required to contact [CONTACT_903124]  
b  The stop date of all related AEs will be actively solicited. For other events, the investigator will provide the stop 
date when it becomes available. AEs for which no stop date was obtained during the course of the study will be 
considered as ongoing at the end of the study.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 55 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 56 of 71 • Other unsolicited non- serious AEs will be classified accor ding to the following intensity scale:  
• Grade 1: No interference with activity  
• Grade 2: Some interference with activity  
• Grade 3: Significant; prevents daily activity  
• Action taken for each AE, if any (e.g., medication) 
The action taken by [CONTACT_98627]’ parents/ guardians to treat any unsolicited AEs  will 
be classified in the eCRF using the following scale: 
0: None 
1: Medication (self -medication with an existing prescription or over- the-counter medication) 
2: Health care provider contact (no new medication prescribed)  
3: Health care provider contact [CONTACT_190638] a new medication (health care provider 
instructed subject to take a new medication, either an over -the-counter medication or one 
requiring a written prescription)  
• Whether the AE led to  discontinuation 
• Whether the AE was related to vaccination (for unsolicited systemic AEs)  
[IP_ADDRESS].4 Serious Adverse Events 
Information on SAEs will be collected and assessed throughout the trial, from inclusion until 
6 months after vaccination. 
Any SAE occurring at any time during the trial will be reported by [CONTACT_892072]. All information 
concerning the SAE is to be reported, either as part of the initial reporting or durin g follow-up 
reporting if relevant information became available later (e.g., outcome, medical history, results of investigations, copy of hospi[INVESTIGATOR_35286]). The Investigator will assess the causal relationship between the SAE and the investigational product as either “Not related” or “Related”, as described in  Section [IP_ADDRESS].7. 
See Section 10 fo r further details on SAE reporting. 
[IP_ADDRESS].[ADDRESS_1266787] will  be assessed in this study. 
[IP_ADDRESS].6 Medically Attended Adverse Event s 
MAAEs that occur from V01 (D0) to V02 will be recorded as unsolicited AEs on the DC as part 
of the unsolicited AEs collected for this post -vaccination period. MAAE s that occur from V02 to 
the long-term safety phone call at approximately 6 months after vaccination will be recorded as such in the MA. An MAAE  that occurs within the study but meets the definitio n of an SAE 
should be reported only on the SAE reporting form. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 56 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 57 of 71 [IP_ADDRESS].7 Assessment of Causality  
The Investigator will assess the causal relationship  between each unsolicited systemic AE and 
vaccination as either not related or related, based on the following definitionsa: 
0: Not related – The AE is clearly / most probably caused by [CONTACT_357295]’s underlying condition, therapeutic intervention, or concomitant therapy; or the 
delay between vaccination and the onset of the AE is incompatible with a causal relationship; or the AE started before the vaccination (screening phase, if applicable)  
1:  Related – There is a “reasonable possibility” that the AE was caused by [CONTACT_190644], 
meaning that there is evidence or arguments to suggest a causal relationsh ip 
Note: By [CONTACT_559], all injection site AEs (solicited and unsolicited) and all solicited systemic reactions are considered to be related to vaccination and referred to as reactions, and therefore do not require the Investigator’s opi[INVESTIGATOR_125611]. 
AEs likely to be related to the product, whether serious or not, that persist at the end of the trial 
will be followed up by [CONTACT_125630]’s condition. The Investigator will inform the Sponsor of the date of final disappearance of the event.  
9.3.2 Immunogenicity  
[IP_ADDRESS] Immunogenicity Endpoints  
• Anti-pertussis (PT, FHA, PRN, and FIM) antibody concentrations pre- and post-vaccination 
measured by [CONTACT_28745]-linked immunsorbent assay (ELISA) 
• Anti-diphtheria antitoxin concentration pre- and post -vaccination assessed by [CONTACT_903125]  
• Anti-tetanus antitoxin concentration pre- and post- vaccination measured by [CONTACT_6428]  
[IP_ADDRESS] Immunogenicity Assessment Methods  
Anti-Bordetella pertussis Antibodies  
Assays wil l be performed by [CONTACT_903126]. Purified PT, FHA, PRN, or FIM 2&3  
antigen is adsorbed to the wells of a microtiter plate. Diluted serum samples (test samples, reference standards, and quality controls) are incubated in the wells. Specific antibo dies in the 
serum samples bind to the immobilized antigen to form antigen- antibody complexes. Unbound 
antibodies are washed from the wells, and enzyme-conjugated anti-human immunoglobulin (IgG) is added. The enzyme conjugate binds to the antigen-antibody complex. Excess conjugate is washed away and a specific colorimetric substrate is added. Bound enzyme catalyzes a hydrolytic reaction causing color development. The intensity of the generated color is proportional to the 
                                                
 
a  ICH Guidelines, Clinical Safety Data Management E2A  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 57 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 58 of 71 amount of specific antibody bound to the wells. The results are read on a spectrophotometer 
(ELISA plate reader). An in house reference standard serum assayed on each plate is used to 
calculate the amount of  specific PT, FHA, PRN, or FIM 2&[ADDRESS_1266788] samples in 
ELISA units per milliliter ( EU/mL) by [CONTACT_903127]. The lower 
limit of quantitation (LLOQ ) for the anti- PT, PRN, and FIM ELISA is 4 EU/mL and the LLOQ 
for the anti- FHA ELISA is 3 EU/mL.  
Antibodies to Tetanus Toxin  
Assays will be performed by [CONTACT_903128]. Purified tetanus toxoid is adsorbed to the 
wells of a microtiter plate. Diluted serum samples (test samples, reference standard, and quality 
control) are incubated in the wells. Specific antibodies in the serum samples bind to the immobilized antigen. Unbound antibodies are washed from the wells, and enzyme-conjugated anti-human immunoglobulin (IgG) is added. The enzyme conjugate binds to the antigen-antibody complex. Excess conjugate is washed away and a specific colorimetric subst rate is added. Bound 
enzyme catalyzes a hydrolytic reaction, which caused color development. The intensity of the generated color is proportional to the amount of specific antibody bound to the wells. The results are read on a spectrophotometer (ELISA plate reader). A reference standard assayed on each plate, WHO human standard lot TE3, is used to calcula te the amount of specific anti -tetanus 
antibody in the unitage assigned by [CONTACT_842538] (IU/mL of serum). The LLOQ for the anti-tetanus ELISA is 0.01 IU/mL. 
Antibodies to Diphtheria Toxin  
Assays are performed by a toxin neutralization test at [COMPANY_011] Pasteur. Serial dilutions of human 
sera are mixed with diphtheria challenge toxin and incubated with Vero cells that are sensitive to the toxin. Neutralizing antibodies specific to diphtheria toxin contained in the serum samples bind to and neutralize the toxin. The neutralized toxin does not affect cellular viability, therefore the cultured cells continue to metabolize and release carbon dioxide (CO
2), reducing the pH of the 
culture medium. Cell survival correlates with the change in the color of the pH indicator (phenol red to yellow at pH ≤ 7.0) contained in the medium. In the absence of neutralizing antibodies, the challenge toxin reduces cellular metabolism and CO
2 production, therefore the pH does not 
decrease and a color change is not detected. The LLOQ is 0.005 IU/mL.  
9.3.[ADDRESS_1266789] document all SAEs regardless of causal relationship, and notify the Sponsor and the Clinical Research Associate ( CRA) within the notification timelines stated in the following 
sections. The Investigator will give access and provide the Sponsor and the CRA with all necessary information to allow the Sponsor to conduct a detailed analysis of the safety of the investigational products . It is the responsibility of the Investigator to request all necessary 
documentation (e.g., medical records, discharge summary, autopsy) in order to provide comprehensive safety information. All relevant information must then be transcribed into the eSAE Form . 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 58 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266790]’s participation in the trial or experiment must be reported within 
24 hours to the Sponsor’s GPV Department and to the CRA. Every SAE must be reported, even if 
the Investigator considers that it is not related to the vaccine. The SAE form must be signed by a 
licensed physician (MD or D O) for whom the task is listed on the Study Task Delegation and 
Signature [CONTACT_357309].  
The Investigator must complete the “eSAE Form” in the EDC application. After validation, a n e-
mail alert will automatically be sent to the GPV mailbox, the CRA and the Clinical Team Leader 
(CTL). This message will include the country, the study code, the subject number, whether the 
report is initial or a follow -up, the diagnosis and/or symptoms , the seriousness criteria, the 
relationship, if related, and the outcome, if fatal. 
If the EDC system is unavailable, the site must notify the Sponsor using the paper version of the SAE Reporting Form, as follows: 
The Investigator must complete the SAE Reporting Form, check off the “Initial Reporting Form” 
box, and send it to the Sponsor by [CONTACT_29553]: 
• By [CONTACT_6791], to the following number:  
• In PDF format to the following e-mail address, using a method of transmission that 
includes password protection:  
• By [CONTACT_29554], to the following address: 
[COMPANY_011] Pasteur Inc. Reception and Triage— Case Management  
Global Pharma coVigilance  
Mail Drop 45D38 Discovery Drive Swiftwater, PA [ADDRESS_1266791] be updated within 24 hours after the Investigator has become aware of any new relevant information concerning the SAE (e.g., outcome, precise description of medical history, results of the investigation). After validation, an e- mail alert will 
be sent automatically to the GPV Department and to the CRA. All relevant information must be 
included directly in the eSAE form. Copi[INVESTIGATOR_84351] (e.g., medical records, discharge summary, autopsy) may be requested by [CONTACT_167545].   
The anonymity of the subject must always be respected when forwarding this information. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 59 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266792] be evaluated  by [CONTACT_3786], using the following definitions: 
0 - Not related : The AE is clearly  / most probably caused by [CONTACT_29549], therapeutic intervention, or concomitant therapy; or the delay between vaccination and the  onset of the SAE is incompatible with a causal relationship; or the SAE 
started before the vaccination  (screening phase, if applicable) . 
1 - Related : There is a “reasonable possibility” that the SAE was caused by [CONTACT_190644], 
meaning that there is evi dence or arguments to suggest a causal relationship.  
(ICH Guidelines, Clinical Safety Data Management E2A) 
Following this, the Sponsor’s Product Safety Officer (PSO)  will also assess the causal relationship 
to the product, based on the available information and current medical knowledge. 
The decision to modify or discontinue the trial may be made after mutual agreement between the 
Sponsor and the Investigators. 
10.5 Reporting SAEs to Health Authorities and IECs  / IRBs 
The Sponsor will inform the relevant health authorities of any reportable SAEs according to the 
local regulatory requirements. Reporting to the health authorities will be according to the 
Sponsor’s standard operating procedures. 
The Sponsor’s Responsible Medical Officer , will notify the Investigators in writing of the 
occurrence of any reportable SAEs. The Investigators / Sponsor will be responsible for informing 
the IECs or IRBs that reviewed the trial protocol.  
11 Data Collection and Management  
11.1 Data Collection and CRF Completion  
Individual safety DCs , specifically designed for this trial by [CONTACT_125633], will be given to study subjects for the recording of daily safety information as described in 
Section [IP_ADDRESS].2. These DCs will include prelisted terms and intensity scales ( see Table 9.1 and 
Table 9.2) as well as areas for free text to capture additional safety information or other relevant 
details. Memory aids will be provided to collect safety informatio n between V02 and the long-
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 60 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 61 of 71 term safety call. Subjects or subjects’ parents or guardians will also be provided with rulers for 
measuring the size of injection site reactions, and with standard digital thermometers for 
measuring daily temperatures. To ensure consistency of reporting, the study sites will instruct subjects or subjects’ parents or guardians on how to correctly use these tools. 
At specified int ervals, the Investigator or an authorized designee will interview the  subjects or 
subjects’ parents or guardians to collect the relevant information recorded in the DC or the MA , 
and will attempt to clarify anything that is incomplete or unclear. All clinical trial information 
gathered by [CONTACT_903129] a web-based eCRF. (Any information that was not documented in the DC will first be captured in the source document and then re ported electronically.) The eCRF has been 
designed specifically for this trial under the responsibility of the Sponsor, using a validated Electronic Records/Electronic Signature -compliant platform (21 CFR Part 11). 
To ensure the correct and consistent comp letion of the eCRFs, the Sponsor or authorized 
representative will provide all necessary tools, instructions, and training to all site staff involved in data entry prior to study start. Additional instructional documents such as training manuals and completion guidelines will be provided to assist with data entry during the course of the trial.  
Upon completion of training, each user requiring access to the EDC system will be issued a unique username [CONTACT_2383]. In the event of a change in trial personnel, each newly assigned individual will receive a unique username [CONTACT_2383]; the username [CONTACT_35395] a previous user may not be reissued. If any trial personnel leave the study, the Investigator is responsible for informing the Sponsor immediately so that their access is deactivated. An audit trail will be initiated in the EDC system at the time of the first data entry in order to track all modifications and to ensure database integrity. 
The Investigator is responsible for the timeliness, completeness,  and accuracy of the information 
in the eCRFs; must provide explanations for all missing information; and must sign the e CRF 
using an e-signature. 
11.2 Data Management  
Management of Clinical Data  
Data generated during the trial will be managed following two dif ferent processes:  
• Clinical data, defined as all data reported in the eCRF, and laboratory data will be handled 
by [CONTACT_1034]’s Clinical Data Management (CDM) platform or authorized representative.  
• Data pertaining to SAEs, which are reported by [CONTACT_190649], will be handled by [CONTACT_1034]’s GPV  Department.  
During the trial,  clinical data reported in the e CRFs will be integrated into the clinical database 
under the responsibility of the [COMPANY_011] Pasteur  CDM platform . Data monitoring at the sites and 
quality control in the form of computerized logic and/or consistency checks will be systematically applied in order to detect errors or omissions. In addition, data reviews may be performed several times by [CONTACT_1034]’s staff in the course of the trial. Any questions pertaining to the reported 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 61 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 62 of 71 clinical data will be submitted to the investigator for resolution using the EDC system. Each step 
of this process will be monitored through the implementation of individual passwords to maintain 
appropriate database access and to ensure database integrity.  
The validation of the immunogenicity data will be performed at the laboratory level following the 
laboratory’s procedures. Information from the laboratory will be checked for consistency before integration into the clinical database.  
After integration of all corrections in the complete set of data, and after the SAE information available from CDM and the GPV Department has been reconciled, the database will be released for 
statistical analysis.  
SAE Data Management  
During the trial, data pertaining to SAEs reported on eSAE Forms will be integrated into the 
Sponsor’s centralized GPV  database. 
Upon receipt of an eSAE Form, the data will be entered into the GPV  database after a duplicate 
check. Each SAE case will be assigned a case identification number. All cases will be reviewed and assessed by [CONTACT_903130]. Each case is reviewed, locked, and approved in the GPV database 
before being reported to the relevant authorities as necessary. Follow-up information concerning a locked and approved case will be entered into the GPV database, and a new version of the case 
will be created.  
The information pertaining to SAEs in the GPV  database will be reconciled with that in the 
clinical database.  
11.3 Data Review 
A blind review of the data is anticipated through the data review process led by D ata Management 
before database lock.  
12 Statistical Methods and Determination of Sample Size  
12.1 Statistical Methods  
12.1.1 Statistical Methods for Demographics and Background Char acteristics  
Summaries of the recruitment and baseline demographic characteristics of the stu dy subjects will 
be presented. The number of subjects enrolled and their age at enrollment (mean, median, and 
minimum and maximum), sex, and ethnic origin will be summarized, along with the number and description of protocol violations.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 62 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 63 of 71 12.1.2 Statistical Meth ods for Observational Objectives 
Safety/Reactogenicity  
The number and percentage of subjects reporting any solicited injection site reactions and 
solicited systemic re actions will be summarized by [CONTACT_2060], intensity (Grade 1, Grade 2, and 
Grade 3), and period (Days 0 to 3, Days 4 to 7, and Days 0 to 7 after vaccination) for each reaction term. For a time period in which more than [ADDRESS_1266793] (Clopper-Pearson) 2- sided 95% confidence intervals (CIs) will be calculated 
for the percentages. 
Immediate reactions, unsolicited AEs (including MAAEs), and SAEs will be coded and presented 
by [CONTACT_167502]. The number and percentage of subjects reporting s afety 
findings will be summarized by [CONTACT_903101], and SOC that has at least 
[ADDRESS_1266794]-vaccination GMCs to the following:   
• In adolescents and adults: booster response rates and antibody GMCs after a single Adacel® 
dose. 
Booster Response Rates partially adjusted  for individual and population differences in pre-
vaccination antibody concentrations.  
The criterion for demonstrating a pertussis booster response  is as follows:  
• If the pre-booster vaccination concentration is < 4xLLO Q, then the post-booster vaccination 
concentration is ≥ 4x the pre- booster concentration* 
• If the pre-booster vaccination concentration is ≥ 4xLLOQ, then the post-primary vaccination 
concentration is ≥ 2x the pre- booster concentration. 
* Pre-booster vaccination concentrations < LLOQ will be converted to LLOQ for purposes of 
calculating this booster response.  
• In older adults: booster response rates to pre- determined criteria and antibody GMCs after 
3 doses of DTaP (Daptacel®) vaccine given to infants in the h istorical Sweden I efficacy trial 
(for FHA, PRN and FIM) or after 4 doses of Daptacel vaccine given to per- protocol subjects 
in [COMPANY_011] Pasteur Study M5A10 (for PT)  
For sera obtained after vaccination, in addition to unadjusted GMCs, GMCs will be computed 
using analysis of covariance to adjust for baseline disparities.  
For diphtheria and tetanus , immunogenicity of the investigational formulations in each of the age 
groups will be assessed by [CONTACT_903131], seroprotection rates and post-vaccination GMCs after a single Adacel
® dose.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 63 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 64 of 71 For diphtheria and tetanus  the criteria for demonstrating a booster response  are as follows:  
• Subjects whose pre-vaccination antibody concentrations are < 0.1 IU/mL will demonstrate the 
booster response if th ey have a post-vaccination level ≥ 0.4 IU/mL 
• Subjects whose pre-vaccination antibody concentrations are ≥ 0.1 IU/mL but < 2.0 IU/mL will 
demonstrate the booster response if they have a 4-fold rise (i.e., post- /pre-vaccination  
≥ 4) 
• Subjects whose pre- vaccination antibody concentrations are ≥ 2.0 IU/mL, will demonstrate the 
booster response if they have a 2 -fold response (i.e., post- /pre-vaccination ≥ 2) 
Seroprotection rates will be presented separately for diphtheria and tetanus as:  
• Proportion of subjects pre - and post- vaccination with anti -diphtheria antitoxin concentration 
≥ 0.01, ≥ 0.10, and ≥ 1.0 IU/mL 
• Proportion of subjects pre- and post- vaccination with anti -tetanus antitoxin concentration 
≥ 0.01, ≥ 0.10, and ≥ 1.0 IU/mL 
As an observational control, pre-and post- vaccination GMCs and booster response rates (for 
pertussis, diphtheria, and tetanus), as well as seroprotection rates (for diphtheria and tetanus only) 
will also be calculated for adolescent, adult, and older adult subjects who receive B OOSTRIX®. 
12.2 Analysis Sets  
12.2.1 Full Analysis Set  
The full analysis set ( FAS) is defined as the subset of randomized subjects who received at least 
one dose of the study vaccine. 
12.2.2 Safety Analysis Set 
The safety analysis set (SafAS) is defined as those subjects who have rec eived study vaccine . All 
subjects will have their safety analyzed according to the vaccine they actually received . Safety 
data recorded for a vaccine received out of the protocol design will be excluded from the analysis 
(and listed separately).  
12.2.3 Per-Protocol Analysis Set  
The per-protocol analysis set (PPAS) is a subset of the FAS. The subjects presenting with at least 
one of the following relevant protocol deviations will be excluded from the PP AS: 
• Subject did not meet all protocol-specified inclusion criteria or met at least one of the 
protocol-specified exclusion criteria  
• Subject did not receive vaccine  
• Subject received a vaccine other than the one that he/ she was randomized to receive  
• Preparation and/or administration of vaccine was not done as per-protoc ol 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 64 of 72

[COMPANY_011] Pasteur ADC01 
Protocol Version 3.0  
Confidential/Proprietary Information  
Page 65 of 71 •Subject did not receive vaccine in the proper time window
•Subject did not provide post -dose serology sample in the proper time window or a post-dose
serology sample was not drawn
•Subject received a protocol -prohibited medication
•Subject’s serology sampl e did not produce a valid test result
12.2.[ADDRESS_1266795]- vaccination titer 
reported as < LLOQ will be converted to a value of 0.5 LLOQ. For the calculation of 4 -fold rise, 
any pre-vaccination value reported as < LLOQ will be converted to LLOQ, and any post-
vaccination titer reported as < LLOQ will be converted to a titer of 0.5  LLOQ when only either the 
numerator or the denominator is <  LLOQ. If both numerator  and denominator are < LLOQ, then 
both will be converted in the same way so that the 4- fold rise is defined as 1. Any titer reported as 
> ULOQ (upper limit of quantitation) will be converted to ULOQ.  
Missing data will not be imputed. No test or search for outliers will be performed.  
12.4 Interim/Preliminary  Analysis 
No interim analyses are planned . An initial internal safety review (ESDR) for this study is 
planned when all adult subjects have been vaccinated and have provided safety data for V01 through V02 post-vaccination, using the data collection methods described in the protocol. The safety data collected will be entered into the electronic case report forms (eCRFs), and will be summarized and reviewed in a per -group partially blinded (group unblinded) fashi on by [CONTACT_429]. It is understood that this review will be based on preliminary data that have not been subject to validation and database lock. No statistical adjustment is necessary because no hypotheses will be tested. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 65 of 72

[COMPANY_011] Pasteur ADC01 
 Protocol Version 3.0  
Confidential/Proprietary Information  
Page 66 of 71 12.5 Determination of Sample Size and  Power Calculation  
Although there are no statistically powered hypotheses in this study, the overall study cohort 
(N=1350) will provide a probability of approximately 93% of observing any AE with a true incidence of 0.2%. For each formulation (N=225), there is a probability of approximately 95% of observing any AE with a true incidence of 1.3%, and a probability of approximately 36% of observing any AE with a true incidence of 0.2%. 
Assuming a drop-out rate of approximately 10%, a total of 67 evaluable subj ects per group is 
anticipated. 
13 Ethical and Legal Issues and Investigator/ Sponsor Responsibilities  
13.[ADDRESS_1266796] of the Trial /Good Clinical Practice  
The conduct of this trial will be consistent with the standards established by [CONTACT_357304] (GCP) as well as with 
all local and/or national regulations and directives.  
13.2 Source Data and Source Documents 
“Source data” are the data contained in source documents. Source documents are or iginal 
documents or certified copi[INVESTIGATOR_014], and include, but are not limited to, DCs , medical and hospi[INVESTIGATOR_2553], screening logs, informed consent /assent forms, telephone contact [CONTACT_29543], and worksheets. 
The purpose of trial source documents is to document the existence of subjects and to substantiate the integrity of the trial data collected. Investigators must maintain source documents so that they are accurate, complete, legible, and up to date. 
For missing or discrepant data on a DC, the study coordinator will  obtain verbal clarification  from 
the subject, enter the response into the "investigator’s comment" page of the DC, and transfer the 
information to the e CRF. 
The subject pre -screening  log should list all individuals contact[CONTACT_357305], regardless of the outcome. 
The Investigator must print
a any electronic records on an ongoing basis, sign and date them 
immediately after creation, and keep the printouts on file as source documents that can be verified 
by [CONTACT_167547]. Any later changes of an electronic record require the record to be re -printed, dated (with an indication of the date of change), and 
signed. Such records must also be kept together with the original printed copy. 
                                                
 
a  Unless the electronic medical records are managed by [CONTACT_35385] 
21 CFR Part 11, in which case they are acceptable on their own.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 66 of 72

[COMPANY_011] Pasteur ADC01 
Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266797] Records  
Prior to initiation of the trial, the Investigator will sign a fully executed confidentiality agreement 
with [COMPANY_011] Pasteur . 
[COMPANY_011] Pasteur personnel (or designates), the IECs/IRBs, and regulatory agencies, including the  
Food and Drug A dministration, require direct access to all study records, and will treat these 
documents in a confidential manner. 
13.4 Monitoring, Auditing, and Archiving  
13.4.1 Monitoring   
Before the start of the trial (i.e., before the inclusion of the first subject in the first center) the 
Investigators and the Sponsor’s staff or a representative will meet at the site -initiation visit to 
discuss the trial protocol and the detailed trial procedures. Emphasis will be placed on inclusion and exclusion criteria, visit timing, safety procedures, informed consent procedures, SAE reporting procedures, eCRF completion, and the handling of samples and products. The Sponsor’s staff or a representative will ensure and document that all material to be used  during the trial has 
been received at the site; and that the study investigator team and local Sponsor /delegate staff 
have been properly informed about the trial, GCP and regulatory requirements, and the Sponsor’s procedures. Specific training sessions for the study investigator team and the CRAs on these 
topi[INVESTIGATOR_35291], and should be documented. 
The following instruction manuals will be provided: the eCRF Completion Guide lines for 
entering data into the eCRF, and the OG for detailed trial procedures such as the product 
management and sample-handling procedures. 
After the start of the trial, the Sponsor’s staff or a representative will be in regular contact [CONTACT_125638]-up visits. The Investigator or delegate must be available for these visits, and must allow the Sponsor/delegate staff direct access 
to subject medical files and eCRFs. During these visits, the Sponsor/delegate staff will: 
•Evaluate the quality of the trial progress (adherence to protocol and any study- specific
guidelines, quality of data collection and document completion, signature [CONTACT_35396],occurrence of SAEs, sample and product management, cold-chain monitoring, archiving)
•Source-verify completed eCRFs and any corresponding answered queries
•Determine the number of complete or ongoing issues identified at monitoring visits (e.g.,
protocol deviations , SAEs). Any identified problems will be discussed with  the Investigator,
and corrective or preventive actions wil l be determined, as appropriate
•After all protocol procedures have been completed and the data have been entered into the
CRF, the Investigator must still be available to answer any queries forward ed by [CONTACT_1034].
All data-related queries must be completed prior to database lock
At the end of the trial, a close-out visit will be performed to ensure that: 
•The center has all the documents necessary for archiving
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 67 of 72

[COMPANY_011] Pasteur ADC01 
Protocol Version 3.0  
Confidential/Proprietary Information  
Page 68 of 71 •All samples have been shipped to the appropriate laboratories
•All unused materials and products have been either destroyed or returned to the Sponsor
13.4.2 Audits and Inspections  
A quality assurance audit may be performed at any time by [CONTACT_1034]’s Clinical and Medical 
Quality O perations or by [CONTACT_903132], GCP and ICH requirements, and other applicable regulations. An 
inspection may be conducted by [CONTACT_12721]. The Investigator must allow direct access to trial documents during these inspections and audits.  
13.4.[ADDRESS_1266798] keep all trial documents after the completion or discontinuation of the trial, 
whatever the nature of the investigational center (private practice, hospi[INVESTIGATOR_307], or institution),  for as 
long as required by [CONTACT_774]. In the absence of any applicable laws or regulations, trial documents will be kept at a minimum for the duration indicated on the Clinical Trial Agreement (CTA) . In no event, should study personnel destroy or permit the destruction of 
any trial documents  upon less than 90 days advance written notification to the Sponsor. In 
addition, trial documents should continue to be stored, at Sponsor's sole expense, in the event that the Sponsor requests in writing that such storage continues for a period of time that exceeds that 
required by [CONTACT_357307] . The Investigator will inform [COMPANY_011] 
Pasteur of any address change or if they will no longer be able to house the trial documents. 
Archived data may be held on electronic records, provided that a back-up exists and that a hard 
copy can be obtained if required. The protocol, documentation, approvals, and all other documents related to the trial, including certificates attesting t hat satisfactory audit and inspection 
procedures have been carried out, will be kept by [CONTACT_35389] (TMF). Data on AEs are included in the TMF. All data and documents will be made available if requested by [CONTACT_190660].  
13.[ADDRESS_1266799] and Insurance Coverage  
A Clinical Trial Agreement will be signed by [CONTACT_125639]’s performance, if relevant. The Sponsor has an insurance policy to cover any liabilities that may arise from use of the product and/or the study protocol. 
13.[ADDRESS_1266800] be submitted to [COMPANY_011] Pasteur  for review before submission 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 68 of 72

[COMPANY_011] Pasteur ADC01 
Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266801] 90  days prior to submission for publication /presentation. 
Any information identified by [CONTACT_903133], 
it being understood that the results of this trial are not to be considered confidential.  
[COMPANY_011] Pasteur’s review can be expedited to meet publication guidelines. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 69 of 72

[COMPANY_011] Pasteur ADC01 
Protocol Version 3.0  
Confidential/Proprietary Information  
Page [ADDRESS_1266802]  
1 Tiw
ari TSP. Tetanus. In: Heyman D ed. Control of Communicable Diseases Manual 20th 
ed. Washington, DC: American Public Health Association; 2015: 607-613. 
2 American Academy of Pediatrics. Tetanus. In Kimberly DW, Brady MT, Jackson MA, 
Long SS, eds. Red Book: 2015 report of the committee on infectious diseases. 30th ed. Elk 
Grove Village, IL: American Academy of Pediatrics; 2015: 773-777. 
3 Diphtheria. Division of Immunizations and Respi[INVESTIGATOR_146044], Health Canada, 2014. 
Available at: http://www.phac -aspc.gc.ca/im/vpd -mev/diptheria- diphterie-eng.php.Accessed 
[ADDRESS_1266803] 2015. 
4 Pertussis. Division of Immunization and Respi[INVESTIGATOR_146044], Health Canada, 2014. 
Available at: http://www.phac -aspc.gc.ca/im/vpd -mev/pertussis-eng.php. Accessed [ADDRESS_1266804] 2015. 
5 Postels-Multani S, Schmitt HJ, Von Konig CHW, Bock HL, Bogaerts H. Symptoms and 
complications of pertussis in adults. Infection 1995; 23: 139-142. 
6 Chatterjee A, O'Keefe C, Varman M, Klein NP, Luber S, Tomovici A, Noriega F. 
Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5- component acellular pertussis vaccine in infants and toddlers: 
a randomized, controlled, open-label, multicenter study. Vaccine. 2012 May 14;30(23):3360-8. 
7 Adacel [package insert].  [COMPANY_011] Pasteur Limited (Toronto, Canada). 
8 BOOSTRIX [package insert]. GlaxoSmithKline Biologicals (Rixensart, Belgium) and [COMPANY_001] Vaccines and Diagnostics GmbH (Marburg, [LOCATION_013]). 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 70 of 72

[COMPANY_011] Pasteur ADC01 
Protocol Version 3.0  
Confidential/Proprietary Information  
Page 71 of 71 15 Signature [CONTACT_892079]/Proprietary Information 
              
ADC01
Protocol Version 3.[ADDRESS_1266805] Code
SP0173
Document Name
[CONTACT_892080]
-
-
-
Approver Name [CONTACT_1782]
(Universal Time)Reason for Signature
[CONTACT_903134] (sanofi pasteur)19 May 2016
10:30:27I am approving this document
Approval
Director of Clinical
Development (sanofi pasteur)19 May 2016
10:34:39I am approving this document
-
-
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
              
ADC01
Protocol Version 3.0
Page 72 of 72
